Marine ecosystem resources for new drug discovery {#s1}
=================================================

The marine ecosystem is most complex and largest aquatic systems on earth. It includes oceans, intertidal ecology, salt marsh, lagoons, estuaries, coral reefs, mangroves, deep sea, sea floor etc. Marine ecosystem has a enormous variety of organisms that are different in their physiology and adaptations and most of the marine life is found in coastal habitats (Hedgepeth, [@B49]). According to the Global Biodiversity Assessment by the United Nations Environment Program, oceans consist of 178,000 marine species in 34 phyla. It is estimated that 10^2^ fungi, 10^3^ bacteria and 10^7^ viruses are likely to exist in one milliliter of seawater (Kubanek et al., [@B68]). Marine organisms comprise around 50% of the total biodiversity on earth. These organisms have shown remarkable contribution in the discovery and production of novel biomolecules (Jimeno et al., [@B60]; Vignesh et al., [@B167]). During 1981--2002 50% of US- FDA approved drugs are reported from either marine bioactive compounds or their synthetics analogs (Vinothkumar and Parameswaran, [@B168]). Cytosine arabinoside, Ara-C (anticancer) and adenine arabinoside, Ara-A (antiviral) were first discovered in the early 1950s and approved by Food and Drug Administration (US-FDA). These drugs were isolated from Caribbean sponge (*Cryptotheca crypta*), as spongouridine and spongothymidine. Blunt et al. ([@B8]) reported more than 20,000 natural bioactive compounds have been obtained from marine environment in last 50 years (Blunt et al., [@B8]). Out of these 9 were approved as drugs and many of them are still in clinical trials. It is well documented that more than 50% of drugs that are in clinical use today belong to the nonribosomal peptides or mixed polyketide-NRP families (Hranueli et al., [@B52]; Agrawal et al., [@B1]; Table [1](#T1){ref-type="table"}). Marine microbes contributes 70% of discovery of NRPs with antimicrobial, antiviral, cytostatic, immunosuppressant, antimalarial, antiparasitic, animal growth promoters and natural insecticides activities etc. (Vinothkumar and Parameswaran, [@B168]). Which makes marine microbial an important bioresource for getting NRPs with numerous pharmaceutical applications. The examples of some NPR based drugs which are now in the market are Daptomycin (antibiotics), Bleomycin (antitumor), Bacitracin (antibiotics for skin infections), Cyclosporin (antifungal and immunosuppressant drugs) (Figure [1](#F1){ref-type="fig"}) (Strieker et al., [@B146]). Norine is the first database entirely dedicated to NRPs and contains more than 1186 entries (Caboche et al., [@B16], [@B17]). In this review we focus on antimicrobial and anticancer NRPs reported from marine microbes with their biological targets.

###### 

List of some marine derived NRPs and their present status (Newman and Cragg, [@B113]; Fenical, [@B32]; Jimenez et al., [@B59]; Petit and Biard, [@B127]).

  **Metabolite**                      **Source**                                                            **Pharmacological activity**   **R&D stage**
  ----------------------------------- --------------------------------------------------------------------- ------------------------------ ---------------
  Ecteinascidin 743 (Yondelis^TM^)    *Ecteinascidia turbinate* (Sea squirt)                                Anticancer                     Market
  Cephalosporine                      *Cephalosporium acremonium* (Fungi)                                   Antibiotic                     Market
  Bengamide derivative (LAF389)       *Jaspis* sp. (Sponge)                                                 Anticancer                     Phase I
  Hemiasterlin derivative (HTI-286)   *Cymbastella* sp. (Sponge)                                            Anticancer                     Phase I
  Dehydrodidemnine B (Aplidine^TM^)   *Aplidium albicans* (Tunicate)                                        Anticancer                     Phase II
  Dolastatin 10                       *Dolabella auricularia* (Mollusc and Cyanobacteria)                   Anticancer                     Phase II
  Kahalalide F                        *Elysia rufescens* (Sea slug)                                         Antitumor                      Phase II
  Bryostatin 1                        *Bugula neritina* (Bryozoan)                                          Anticancer                     Phase III
  Diazonamide                         *Diazona angulata* (Tunicate)                                         Anticancer                     Preclinical
  Thiocoraline                        *Mi Cromonospora marina* (Bacteria)                                   Anticancer                     Preclinical
  Vitilevuamide                       *Didemnum cucliferum* and *Polysyncraton lithrostrotum* (Tunicates)   Anticancer                     Preclinical

![Structures of marketed NRPs.](fphar-08-00828-g0001){#F1}

Nonribosomal peptide and their bio combinatorial synthesis {#s2}
==========================================================

An extensive literature on biosynthesis of non-ribosomal peptides is available in previous reviews (Sieber and Marahiel, [@B141]; Finking and Marahiel, [@B34]; Caboche et al., [@B17]; Strieker et al., [@B146]; Pfennig and Stubbs, [@B129]). Here we just summarized how NPRs are synthesized biologically, biomolecular structural architecture and enzymatic machinery of non-ribosomal peptide synthetases (NRPSs). NRPs are peptide secondary bioactive metabolites synthesized by a multi-modular enzyme complex called nonribosomal peptide synthetases (NRPSs) found only in bacteria, cyanobacteria and fungi (Matsunaga and Fusetani, [@B92]; Nikolouli and Mossialos, [@B116]). NRPs are formed from a series of enzymatic transformations employing a much more diverse set of precursors and biosynthetic reactions. NRPSs utilize both proteinogenic and nonproteinogenic amino acids (not encoded by DNA) as building blocks for the growing peptide chain (Finking and Marahiel, [@B34]; Felnagle et al., [@B31]). Moreover, these secondary bioactive metabolite peptides contain unique structural features, such as D-amino acids, N-terminally attached fatty acid chains, N- and C-methylated residues, N- formylated residues, heterocyclic elements, and glycosylated amino acids, as well as phosphorylated residues etc.; (Sieber and Marahiel, [@B141]). As a result, NRPs exhibit a broad spectrum of biological activities, ranging from antimicrobial to anticancer (Hur et al., [@B54]). The macrocyclic structure is a common feature of nonribosomally synthesized bioactive peptides, which is responsible for reduction in structural flexibility and may, therefore, constrain them into the biologically active conformation (Sieber and Marahiel, [@B141]; Grünewald and Marahiel, [@B39]).

The discovery of NRPs began when Tatum and colleagues (Mach et al., [@B84]) provided first evidence that tyrocidine, a cyclic decapeptide produced by *Bacillus brevis*, was biosynthesized by a mechanism independent of the ribosome (Mankelow and Neilan, [@B87]). They found that protein synthesis in *B. brevis* was inhibited by using ribosome targeting antibiotics like chloramphenicol and chlortetracycline, however, the biosynthesis of tyrocidine was not obstructed by the same. Additional biochemical analyses demonstrated that gramicidin S, a cyclic decapeptide produced by *B.brevis*, did not include tRNA molecules or aminoacyl-tRNA-synthetases (Nikolouli and Mossialos, [@B116]; Figure [2](#F2){ref-type="fig"}). Further work by Lipmann established that the production of cyclic decapeptide, gramicidin is an ATP-dependent reaction, catalyzed by these enzymes incorporating amino acids in a two-step process by their modules and their respective domains. The first step involves release of pyrophosphate (PPi) and the second step releases adenosine monophosphate (AMP), with the end result being an amino acid covalently linked to the enzyme (Wu et al., [@B178]). These finding suggested that tyrocidine and gramicidin S peptide synthesis did not involve ribosomal machinery for their synthesis, which leads to discovery of the NRPs and NRPSs. These data also gave the first indication of an amino acid as a "carrier" being involved in NRPS enzymology (Felnagle et al., [@B31]; Condurso and Bruner, [@B21]; Figure [3](#F3){ref-type="fig"}).

![Tyrocidine biosynthesis in bacteria *B. brevis* nonribosomal peptide synthetases of tyrocidine synthesis mainly consist, three NRPSs TycA, TycB, and TycC, which contain 10 modules (TycA comprises one module, TycB three, and TycC six modules) each of those responsible for the incorporation of a cognate amino acid into the growing chain with the help of their domains. The Te domain at the last module of TycC catalyzes peptide cyclization and thereby release of the final product (Mootz et al., [@B109]).](fphar-08-00828-g0002){#F2}

![The Gramicidin S biosynthetic machinery the enzymatic assembly consists of two NRPSs (GrsA and GrsB) and their modules, respectively. Each module is responsible for the incorporation of one monomeric amino acid. The thioesterase domain (TE domain) catalyzes the dimerization of two assembled pentapeptides and subsequent cyclization, resulting in gramicidin S (Hoyer et al., [@B51]).](fphar-08-00828-g0003){#F3}

The biosynthetic study of NRP compounds is challenging if we consider their complexity and biological activities. Each nonribosomal peptide synthetase is composed of an array of distinct modular sections, each of which is responsible for the incorporation of one defined monomer into the final peptide product. Biosynthesis of a nonribosomal peptide by NRPSs involves a series of repeating reactions that are catalyzed by the coordinated actions of modules and their core catalytic domains. Each enzyme module contains three catalytic domains: adenylation domain (A), peptidyl-carrier (PCP) domain and condensation domain (C). A final peptide product released from the enzyme through cyclization or hydrolysis that takes place by thioesterase domain (TE) which is located in the final NRPSs module (Figures [4A,B](#F4){ref-type="fig"}; Mankelow and Neilan, [@B87]; Finking and Marahiel, [@B34]). For recent example, Thiocoraline, an anticancer nonribosomal peptide (NRP) synthesis by marine bacteria *Cromonospora marina* contains peptidic backbone of two S-methylated Lcysteine residues. S-Methylation occurs very rarely in nature, and is observed extremely rarely in nonribosomal peptide scaffold. The four modules TioJ, TioO, TioR, and TioS of thiocoraline NRPSs are responsible for the thiocoraline-backbone biosynthesis. TioR and TioS would most probably constitute the NRPSs involved in the biosynthesis of the thiocoraline, according to the colinearity of the respective modules (Figure [5](#F5){ref-type="fig"}; Lombó et al., [@B77]; Al-Mestarihi et al., [@B2]). The potentials of marine microbes to produce NRP\'s with antimicrobial and anticancer activity are reported in this review. The data referring to these activities are depicted in Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"} and the structures are given in Supplementary Materials (Figures [S1](#SM1){ref-type="supplementary-material"}--[S17](#SM1){ref-type="supplementary-material"}).

![**(A)** Organization of modules and their domains in nonribosomal peptide synthetase enzyme. Each module contains their catalytic domains that catalyze activities, substrate activation (A-domain), covalent loading (CP-domain), and peptide bond formation (C-domain). The first modules always lacks a C domain and is used to initiate nonribosomal peptide synthesis, while those harboring a C-domain qualify for elongation and modules with thioesterase domains (TE) usually in the last domain, for termination of peptide product from enzyme through cyclization or hydrolysis (Prieto et al., [@B131]). **(B)** Mechanism of nonribosomal peptide (NRP) synthesis Adenylation domain (A) activates amino acid as aminoacyl-AMP and transfer to PCP domain which condenses coming amino acids by forming peptide bonds. Structural modifications mostly operate by epimerization domains which converts L-amino acid to D-amino acid and vice a versa. Peptide chain thus transfers to TE domain by transesterification reaction by PCP. Finally, TE domain catalyzed product release (NRPs) by either hydrolysis or macrocyclization (Condurso and Bruner, [@B21]).](fphar-08-00828-g0004){#F4}

![Structural organization of the thiocoraline NRPSs. L, AMP-ligase; P, peptidyl-carrier protein domain; C, condensation domain; A, adenylation domain; E, epimerization domain; M, N-methyltransferase domain; TE, thioesterase domain.](fphar-08-00828-g0005){#F5}

###### 

Antimicrobial NRPs from marine microbes.

  **Sr. No**.         **NRPs**                                                                                                          **Chemical architecture**   **Source**                      **Biological target**                   **Biological active value (MIC/IC~50~/GI~50~/ID~50~/ED~50~)**              **References**
  ------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------------- --------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------
  **BACTERIA**                                                                                                                                                                                                                                                                                                         
  1\.                 Bogorol A **(1)**                                                                                                 Linear peptide              *Bacillus laterosporus*         MRSA, VRE                               2 μg/mL, 10 μg/mL                                                          Barsby et al., [@B7]
  2\.                 Nocathiacins I--III **(2--4)**                                                                                    Cyclic peptide              *Nocardia* sp.                  multiple-drug resistant pathogens       0.001--0.015, 0.0005-0.25, 0.002-0.06 μg/mL                                Leet et al., [@B71]; Li et al., [@B74]
  3\.                 YM- 266183 and YM- 266184 **(5--6)**                                                                              Cyclic peptide              *Bacillus cereus*               Staphylococci, Enterococci              0.05--0.2 μg/mL, 0.013--0.025 μg/mL. 0.02--0.05 μg/mL, 0.006--0.01 μg/mL   Nagai et al., [@B111]; Suzumura et al., [@B149]
  4\.                 cyclo-(glycyl-l-seryl-l-prolyl-l- glutamyl) **(7)** and cyclo-(glycyl-l-prolyl-l-glutamyl) **(8)**                Cyclic peptide              *Ruegeria* sp.                  *Bacillus subtilis*                     25 and 50 μg/mL                                                            Mitova et al., [@B104]
  5\.                 Tauramamide **(9)**                                                                                               Lipopeptide                 *B. laterosporus*               *Enterococcus* sp.                      0.1 μg/mL                                                                  Desjardine et al., [@B25]
  6                   Tetrapeptide cyclo-isoleucyl-prolyl-leucyl alanyl **(10)** and cyclo-phenylalanyl-prolyl-leucyl prolyl **(11)**   Cyclic tetra peptide        *Pseudomonas* sp.               Marine bacterial                        --                                                                         Rungprom et al., [@B138]
  7\.                 Unnarmicin A and C **(12--13)**                                                                                   Depsipeptide                *Photobacterium* sp.            *Pseudovibrio*                          7--8 μg/mL                                                                 Oku et al., [@B121]
  8\.                 Thiopeptide TP-1161 **(14)**                                                                                      Cyclic peptide              *Nocardiopsis* sp.              Gram-positive bacteria                  0.25--4 μg/mL                                                              Engelhardt et al., [@B29]
  9\.                 Solonamide A--B **(15--16)**                                                                                      Cyclo depsipeptide          *Photobacterium halotolerans*   *S. aureus*                             --                                                                         Mansson et al., [@B88]
  10\.                Fijimycin A--C **(17--19)**                                                                                       Depsipeptide                *Streptomyces* sp.              MRSA                                    4--16 μg/mL                                                                Sun et al., [@B147]
  11\.                Peptidolipins B--F **(20--24)**                                                                                   Lipopeptide                 *Nocardia* sp.                  MRSA, MSSA                              64 μg/mL                                                                   Wyche et al., [@B179]
  12\.                Kocurin **(25)**                                                                                                  Cyclic peptide              *Kocuria palustris*             MRSA                                    0.25 μg/mL                                                                 Martín et al., [@B90]
  13\.                Champacyclin **(26)**                                                                                             Octapeptide                 *Streptomyces champavatii*      *Erwinia amylovora*                     25 μM                                                                      Pesic et al., [@B126]
  14\.                Ngercheumicin F--I **(27--30)**                                                                                   Cyclo depsipeptide          *P. halotolerans*               *S. aureus*                             5 μg/mL                                                                    Kjaerulff et al., [@B65]
  **CYANOBACTERIA**                                                                                                                                                                                                                                                                                                    
  15\.                Lobocyclamide B **(31)**                                                                                          Cyclododecapeptide          *Lyngbya confervoides*          Fluconazole-resistant *C. albicans*     --                                                                         MacMillan and Molinski, [@B85]
  16\.                Brunsvicamide A--C **(32--34)**                                                                                   Cyclic hexapeptide          *Tychonema* sp.                 *Mycobacterium tuberculosis* (MptpB)    7.3 μM                                                                     Müller et al., [@B110]
  **FUNGI**                                                                                                                                                                                                                                                                                                            
  17\.                Guangomides A--B **(35--36)**                                                                                     Cyclic depsipeptide         Unidentified fungus             *S. epidermis, E. durans*               100 μg/mL 100 μg/mL                                                        Amagata et al., [@B3]
  18\.                11-O-methylpseurotin A **(37)**                                                                                   Linear peptide              *Aspergillus fumigatus*         *Saccharomyces cerevisiae*              --                                                                         Boot et al., [@B9]
  19\.                Emericellamides A--B **(38--39)**                                                                                 Cyclic depsipeptides        *Emericella* sp.                MRSA                                    3.8 and 6.0 μM                                                             Oh et al., [@B118]
  20\.                Scopularides A--B **(40--41)**                                                                                    Cyclododecapeptide          *Scopulariopsis brevicaulis*    Gram-positive bacteria                  --                                                                         Yu et al., [@B183]
  21\.                Alternaramide **(42)**                                                                                            Cyclic Penta depsipeptide   *Alternaria* sp. SF,5016        *B. subtilis* and *S. aureus*           (ZOI 8 mm), (ZOI 13 mm)                                                    Kim et al., [@B64]
  22\.                Trichoderins A, A\', B2 **(43--45)**                                                                              Lipopeptide                 *Trichoderma* sp.               *Mycobacterium tuberculosis*            0.02--2.0 l g/mL                                                           Pruksakorn et al., [@B133]
  23\.                Unguisin E **(46)**                                                                                               Cyclic heptapeptide         *Aspergillus* sp.               Antibacterial                           --                                                                         Liu and Shen, [@B75]
  24\.                Sclerotides A--B **(47--48)**                                                                                     Cyclic hexapeptide          *Aspergillus sclerotiorum*      *C. albicans, Pseudomonas aeruginosa*   7.0 and 3.5 μM. nil and, 35.3 μM                                           Zheng et al., [@B186]
  25\.                Sclerotiotides A--K **(49--59)**                                                                                  Cyclic tripeptide           *A. sclerotiorum* PT06-1        *C. albicans*                           7.5, 3.8, 30, 6.7μM                                                        Zheng et al., [@B185]

###### 

Anticancer NRPs from marine microbes.

  **Sr. No**.         **NRPs**                                                                                                     **Chemical architecture**   **Source**                                                 **Biological target**                                                                                                                       **Biological active value (MIC/IC~50~/GI~50~/ID~50~/ED~50~)**   **References**
  ------------------- ------------------------------------------------------------------------------------------------------------ --------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------
  **BACTERIA**                                                                                                                                                                                                                                                                                                                                                                                                                        
  1\.                 Mixirins A--C **(60--62)**                                                                                   Cyclopeptide                *Bacillus* sp.                                             HCT-116 cells (colon)                                                                                                                       0.68, 1.6, 1.3 μg/ml                                            Zhang et al., [@B184]
  2\.                 Mechercharmycin A **(63)** Mechercharmycin B **(64)**                                                        Cyclic peptide              *Thermoactinomyces* sp.                                    A549 cells (lung), Jurkat cells                                                                                                             4.0 × 10^−8^ M 4.6 × 10^−8^ M                                   Kanoh et al., [@B62]
  3\.                 Bromoalterochromide A **(65)** and A\' **(66)**                                                              Chromo peptide              *Pseudoalteromonas maricaloris*                            *Strongylocentrotus intermedius* eggs                                                                                                       --                                                              Speitling et al., [@B145]
  4\.                 Lucentamycins A--D **(67--70)**                                                                              --                          *Nocardiopsis lucentensis*                                 HCT-116 cells (colon)                                                                                                                       0.20 and 11 μM                                                  Cho et al., [@B19]
  5\.                 Piperazimycins A--C **(71--73)**                                                                             Cyclic hexadepsipeptide     *Streptomyces* sp.                                         HCT-116 cells (colon)                                                                                                                       76 ng/mL                                                        Miller et al., [@B102]
  6\.                 Urukthapelstatin A **(74)**                                                                                  Cyclic thiopeptide          *Mechercharimyces asporophorigenens*                       A549 cells (lung)                                                                                                                           12 nM                                                           Matsuo et al., [@B93]
  7\.                 Arenamides A--C **(75--77)**                                                                                 Cyclo hexadepsipeptide      *Salinispora arenicola*                                    Tumor necrosis factor                                                                                                                       3.7 and 1.7 μM                                                  Asolkar et al., [@B5]
  8\.                 Bacillistatins 1-2 **(78--79)**                                                                              Cyclodepsipeptide           *Bacillus silvestris*                                      P388 (murine lymphocytic leukemia); BXPC-3 (pancreas); MCF-7 (breast); SF-268 (CNS); NCI- H460 (lung); KM20L2 (colon); DU- 145 (prostate)   10^−4^−10^−5^ μg/mL                                             Pettit et al., [@B128]
  9\.                 Turnagainolides A--B **(80--81)**                                                                            Cyclic peptide              *Bacillus* sp.                                             PI3K pathway                                                                                                                                --                                                              Li et al., [@B73]
  10\.                Padanamides A--B **(82--83)**                                                                                Linear tetrapeptide         *Streptomyces* sp.                                         Jurkat cells                                                                                                                                20 μg/mL                                                        Williams et al., [@B170]
  11\.                Ohmyungsamycins A--B **(84--85)**                                                                            Cyclic peptide              *Streptomyces* sp.                                         Cytotoxic                                                                                                                                   359--816 nM and 12.4--16.8 μM                                   Um et al., [@B166]
  12\.                Proximicin A--C **(86--88)**                                                                                 --                          *Verrucosispora* strain MG-37                              AGS (gastric), HepG2 (hepatocellular), MCF 7 (breast)                                                                                       0.6, 1.5, 0.25 μg/mL 0.8, 9.5, 0.7 μg/mL 7.2, 5.0, 9.0 μg/mL    Fiedler et al., [@B33]
  **CYANOBACTERIA**                                                                                                                                                                                                                                                                                                                                                                                                                   
  13\.                Hoiamide A **(89)**                                                                                          Cyclic depsipeptide         An assemblage of *L. majuscula* and *Phormidium gracile*   Voltage-gated sodium channel                                                                                                                92.8 nM                                                         Pereira et al., [@B125]
  14\.                Yanucamides A--B **(90--91)**                                                                                Cyclic depsipeptide         *Lyngbya majuscule* and *Schizothrix* sp.                  Brine shrimp toxicity                                                                                                                       5 ppm                                                           Sitachitta et al., [@B144]
  15\.                Lyngbyabellins A **(92)**                                                                                    Cyclic depsipeptide         *L. majuscula*                                             KB cells LoVo cells                                                                                                                         0.03 and 0.50 μg/mL                                             Luesch et al., [@B81]
  16\.                Lyngbyabellin B **(93)**                                                                                     Cyclic depsipeptide         *L. majuscula*                                             Brine shrimp (*Artemia salina*)                                                                                                             3.0 ppm                                                         Milligan et al., [@B103]
  17\.                Microcyclamide **(94)**                                                                                      Cyclic hexapeptide          *Microcystis aeruginosa*                                   P388 murine leukemia cells                                                                                                                  24--30 μg/mL                                                    Ishida et al., [@B56]
  18\.                Apratoxin A **(95)**                                                                                         --                          *L. majuscula*                                             KB cells and LoVo cancer cells                                                                                                              0.52 nM 0.36 nM                                                 Luesch et al., [@B80]
  19\.                Pitipeptolides A--B **(96--97)**                                                                             Cyclic depsipeptide         *L. majuscula*                                             LoVo cells                                                                                                                                  2.25 and 1.95 μg/mL                                             Luesch et al., [@B78]
  20\.                Ulongamides A--F **(98--103)**                                                                               Cyclic depsipeptide         *Lyngbya* sp.                                              KB and LoVo cells                                                                                                                           1 μM 5 μM                                                       Luesch et al., [@B79]
  21\.                Obyanamide **(104)**                                                                                         Cyclic depsipeptide         *L. confervoides*                                          KB cells                                                                                                                                    0.58 μg/mL                                                      Williams et al., [@B172]
  22\.                Malevamide D **(105)**                                                                                       Linear peptide              *Symploca hydnoides*                                       P-388, A-549, HT-29, and MEL-28                                                                                                             0.7 and 0.7 nM                                                  Horgen et al., [@B50]
  23\.                Tasiamide **(106)**                                                                                          Linear peptide              *Symploca* sp.                                             KB and LoVo cells                                                                                                                           0.48 and 3.47 μg/mL                                             Williams et al., [@B173]
  24\.                Tasiamide B **(107)**                                                                                        Linear peptide              KB                                                         KB cells                                                                                                                                    0.8 μM                                                          Williams et al., [@B171]
  25\.                Guineamides A--F **(108--113)**                                                                              Cyclic depsipeptide         *L. majuscula*                                             Mouse neuroblastoma cells                                                                                                                   15 and 16 μM                                                    Tan et al., [@B152]
  26\.                Homodolastatin 16 **(114)**                                                                                  Cyclic depsipeptide         *L. majuscula*                                             Oesophageal Cervical cells                                                                                                                  4.3 μg/mL 1 μg/mL                                               Davies-Coleman et al., [@B24]
  27\.                Lyngbyastatin 3 **(115)**                                                                                    Cyclic peptide              *L. majuscula*                                             KB and LoVo cells                                                                                                                           32 and 400 nM                                                   Williams et al., [@B171]
  28\.                Ulongapeptin **(116)**                                                                                       Cyclic depsipeptide         *Lyngbya* sp.                                              KB cells                                                                                                                                    0.63 μM                                                         Williams et al., [@B176]
  29\.                Tasipeptins A--B **(117--118)**                                                                              Depsipeptide                *Symploca* sp.                                             KB cells                                                                                                                                    0.93 and 0.82 μM                                                Williams et al., [@B171]
  30\.                Jamaicamides A--C **(119--121)**                                                                             Lipopeptide                 *L. majuscula*                                             H-460 (lung), Neuro-2a. Sodium channel blocking                                                                                             15 μM 5 μM                                                      Williams et al., [@B176]
  31\.                Wewakpeptins A--D **(122--125)**                                                                             Depsipeptide                *Lyngbya semiplena*                                        NCI-H460 neuro-2a                                                                                                                           0.4 μM                                                          Williams et al., [@B174]
  32\.                Trungapeptin A--C **(126--128)**                                                                             Cyclic depsipeptide         *L. majuscula*                                             Ichthyotoxic Brine shrimp toxicity                                                                                                          6.25 ppm 10 ppm                                                 Bunyajetpong et al., [@B12]
  33\.                Aurilides B and C **(129--130)**                                                                             Cyclic peptide              *L. majuscula*                                             NCI-H460 (lung), neuro-2a                                                                                                                   0.01 and 0.13 μM                                                Han et al., [@B45]
  34\.                Belamide A **(131)**                                                                                         Tetra peptide               *Symploca* sp.                                             MCF7 (breast) HCT-116 (colon)                                                                                                               0.74 μM                                                         Simmons et al., [@B142]
  35\.                Lyngbyastatins 5--7 **(132--134)**                                                                           --                          *Lyngbya* sp.                                              Potent Elastase Inhibitors                                                                                                                  3--10 nM                                                        Taori et al., [@B157]
  36\.                Mitsoamide **(135)**                                                                                         Linear peptide              *Geitlerinema* sp.                                         NCI-H460 (lung)                                                                                                                             460 nM                                                          Andrianasolo et al., [@B4]
  37\.                Apratoxin D **(136)**                                                                                        Cyclic depsipeptide         *L. majuscule* and *Lyngbya sordida*                       H-460 (lung)                                                                                                                                2.6 nM                                                          Gutiérrez et al., [@B43]
  38\.                Apratoxin E **(137)**                                                                                        --                          *Lyngbya bouillonii*                                       HT29 (colon), HeLa (cervical),                                                                                                              21--72 nM                                                       Matthew et al., [@B95]
  39\.                Dragonamide C and D **(138--139)**                                                                           Linear lipopeptide          *Lyngbya polychroa*                                        U2OS (osteosarcoma), HT29 (colon), IMR-32 (neuroblastoma)                                                                                   56 and 59 μM 22 and 32 μM 49 and 51 μM                          Gunasekera et al., [@B42]
  40\.                Coibamide A **(140)**                                                                                        Cyclic depsipeptide         *Leptolyngbya* sp.                                         NCI 60 cancer cell                                                                                                                          \< 23 nM                                                        Medina et al., [@B98]
  41\.                Symplostatin 4 **(141)**                                                                                     Linear peptide              *Symploca* sp.                                             Antimitotic to H-460 (lung) neuro-2a                                                                                                        40 nM 29 nM                                                     Taori et al., [@B156]
  42\.                Itralamides A--B **(142--143)**                                                                              Depsipeptide                *L. majuscula*                                             HEK293 cells                                                                                                                                6 ± 1 μM                                                        Jiménez et al., [@B58]
  43\.                Desmethoxymajusculamide C **(144)**                                                                          Cyclic and Liner peptide    *L. majuscula*                                             HCT-116                                                                                                                                     20 nM                                                           Simmons et al., [@B143]
  44\.                Hantupeptin A **(145)**                                                                                      Cyclic depsipeptide         *L. majuscula*                                             MOLT-4 (leukemia) MCF-7 (breast)                                                                                                            32 μM 4.0μM                                                     Tripathi et al., [@B162]
  45\.                Desacetyl-Microcolin B **(146)**                                                                             Linear peptide              *Lyngbya cf. polychroa*                                    HT-29 andIMR-32 cells                                                                                                                       14 nM 14 nM                                                     Meickle et al., [@B100]
  46\.                Palmyramide A **(147)**                                                                                      Cyclic depsipeptide         *L. majuscula*                                             Neuro-2a and H-460                                                                                                                          17.2μM 39.7μM                                                   Taniguchi et al., [@B155]
  47\.                Bisebromoamide **(148)**                                                                                     Linear peptide              *Lyngbya* sp.                                              Protein kinase inhibitor (HeLa S3 cells)                                                                                                    04 μg/mL                                                        Teruya et al., [@B159]
  48\.                Lyngbyabellin J **(149)** Lyngbyapeptin D **(150)**                                                          Linear peptide              *L. bouillonii*                                            Actin-disrupting                                                                                                                            0.041 μM                                                        Matthew et al., [@B94]
  49\.                Grassypeptolides A--C **(151--153)**                                                                         Cyclic depsipeptide         *L. confervoides*                                          HT29 cells HeLa cells                                                                                                                       1.22μM, 4.97μM, 76.7nM 1.01μM, 2.93μM, 44.6 nM                  Kwan et al., [@B69]
  50\.                Hantupeptin B and C **(154--155)**                                                                           Cyclodepsipeptide           *L. majuscula*                                             MOLT-4 cells MCF-7 cells                                                                                                                    0.2 μM 0.5 μM                                                   Tripathi et al., [@B163]
  51\.                Lyngbyacyclamides A--B **(156--157)**                                                                        Cyclic peptide              *Lyngbya* sp                                               B16 mouse melanoma                                                                                                                          0.7 μM                                                          Maru et al., [@B91]
  52\.                Grassypeptolides D--E **(158--159)**                                                                         Cyclic depsipeptide         *Leptolyngbya* sp.                                         HeLa and neuro-2a blastoma                                                                                                                  335 and 192 nM 599 and 407 nM                                   Thornburg et al., [@B161]
  53\.                Grassypeptolides F and G **(160--161)**                                                                      Cyclic depsipeptide         *L. majuscula*                                             Inhibit transcription (AP-1 cell)                                                                                                           5.2 and 6.0 μM                                                  Popplewell et al., [@B130]
  54\.                Veraguamides A--H and J-L **(162--172)**                                                                     --                          *Symploca hydnoides*                                       H-460 (lung)                                                                                                                                141 nM                                                          Mevers et al., [@B101]; Salvador et al., [@B139]
  55\.                Malyngamide 3 **(173)** and Cocosamide A--B **(174--175)**                                                   Cyclic peptide              *L. majuscula*                                             HT-29 cells                                                                                                                                 48 μM, 24 μM, 11μM                                              Gunasekera et al., [@B41]
  56\.                Cyclodepsipeptide **(176--180)**                                                                             Cyclodepsipeptide           *L. majuscula*                                             HT-29 and MCF7                                                                                                                              --                                                              Montaser et al., [@B107]
  57\.                Lagunamide C **(181)**                                                                                       Cyclodepsipeptide           *L. majuscula*                                             HT-29 and MCF7                                                                                                                              2.1--24.4 nM                                                    Tripathi et al., [@B164]
  58\.                Wewakamide A **(182)** Guineamide G **(183)**                                                                Cyclic depsipeptide         *L. semiplena* and *L. majuscula*                          Neuro-2a blastoma                                                                                                                           2.7 μM                                                          Nan et al., [@B112]
  59\.                Porpoisamide A--B **(184--185)**                                                                             Cyclic depsipeptide         *Lyngbya* sp.                                              HCT-116 (colon) cells U2OS (osteosarcoma) cells                                                                                             25, 21μM 28, 22 μM                                              Meickle et al., [@B99]
  60\.                Lyngbyabellin K and L **(186--187)**, 7-epi-lyngbyabellin L **(188)** and Lyngbyabellin M-N **(189--190)**   Lipopeptide                 *Moorea bouillonii*                                        HCT116 (colon) cells                                                                                                                        40.9 ± 3.3 nM                                                   Choi et al., [@B20]
  61\.                Viequeamides A--D **(191--194)**                                                                             Cyclic depsipeptide         *Rivularia* sp.                                            H460 (lung) cells                                                                                                                           60 ± 10 nM                                                      Boudreau et al., [@B10]
  62\.                Symplocin A **(195)**                                                                                        Linear peptide              *Symploca* sp.                                             Cathepsin E inhibitor                                                                                                                       300 pM                                                          Molinski et al., [@B106]
  63\.                Bouillonamide **(196)**                                                                                      Cyclic depsipeptide         *M. bouillonii*                                            Neuron 2a cells                                                                                                                             6.0 μM                                                          Tan et al., [@B151]
  64\.                Malyngamide 4 **(197)**                                                                                      Lipopeptide                 *Moorea producens*                                         HTCLs                                                                                                                                       --                                                              Shaala et al., [@B140]
  65\.                Kurahyne B **(198)**                                                                                         --                          *Okeania* sp.                                              HeLa and HL60                                                                                                                               8.1 and 9.0 μM                                                  Okamoto et al., [@B119]
  **FUNGI**                                                                                                                                                                                                                                                                                                                                                                                                                           
  66\.                N-Methylsansalvamide **(199)**                                                                               Cyclic depsipeptide         *Fusarium strain* CNL-619                                  Tumor cell                                                                                                                                  8.3 μM                                                          Cueto et al., [@B23]
  67\.                Dictyonamides A--B **(200--201)**                                                                            Linear dodecapeptide        Fungus K063                                                Kinase 4 inhibitor                                                                                                                          16.5 μg/mL                                                      Komatsu et al., [@B66]
  68\.                Scytalidamides A--B **(202--203)**                                                                           Cyclic heptapeptide         *Scytalidium* sp.                                          HCT-116 (colon)                                                                                                                             7 and 11.0 μM                                                   Tan et al., [@B150]
  69\.                Trichodermamides A--B **(204--205)**                                                                         Dipeptide                   *Trichoderma virens*                                       HCT-116 (colon)                                                                                                                             0.32 μg/mL                                                      Garo et al., [@B38]
  70\.                Rostratins A--D **(206--209)**                                                                               Cyclic dipeptide            *Exserohilum rostratum*                                    HCT-116 (colon)                                                                                                                             8.5, 1.9, 0.76 and 16.5 μg/mL                                   Tan et al., [@B153]
  71\.                IB-01212 **(210)**                                                                                           Cyclic depsipeptide         *Clonostachys* sp. *ESNA,A009*                             LN-caP (prostrate), SK-BR3 (breast), HT29 (colon) and HELA (cervix)                                                                         10-8 M                                                          Cruz et al., [@B22]
  72\.                Zygosporamide **(211)**                                                                                      Cyclic Penta depsipeptide   *Zygosporium masonii*                                      SF-26 (CNS) RXF 393 (renal)                                                                                                                 6.5 nM ≤ 5.0 nM                                                 Oh et al., [@B117]
  73\.                Trichoderide A **(212)**                                                                                     --                          *Trichoderma reesei*                                       A375-S2 melanoma                                                                                                                            18.5 mg/mL                                                      Sun et al., [@B148]
  74\.                Spicellamide A--B **(213--214)**                                                                             Cyclo hexadepsipeptide      *Spicellum roseum*                                         Neuron 2a cells                                                                                                                             30 μg/mL and 6.2 μg/mL                                          (Kralj et al., [@B67]
  75\.                1962A and 1962B **(215--216)**                                                                               Cyclic depsipeptide         Strain No. 1962                                            MCF-7 (breast)                                                                                                                              100 μg/mL                                                       Huang et al., [@B53])
  76\.                Microsporins A--B **(217--218)**                                                                             Cyclic tetrapeptide         *Microsporum cf. gypseum*                                  HCT-116, Potent inhibitors of HDAC                                                                                                          0.6 μg/mL and 8.5 μg/mL                                         Gu et al., [@B40]
  77\.                Efrapeptin J **(219)**                                                                                       Penta decapeptide           *Tolypocladium* sp.                                        HT1080                                                                                                                                      --                                                              Hayakawa et al., [@B47]
  78\.                Cotteslosin A--B **(220--221)**                                                                              Cyclo pentapeptide          *Aspergillus versicolor*                                   MM418c5 (melanoma), DU145 (prostate), T47D (breast)                                                                                         66 μg/mL 94 μg/mL 90 μg/mL                                      Fremlin et al., [@B36]
  79\.                Versicotide A--B **(222--223)**                                                                              Cyclo pentapeptide          *A. versicolor*                                            Anti-tumor                                                                                                                                  --                                                              Zhou et al., [@B187]
  80\.                Fellutamide F **(224)**                                                                                      Lipopeptide                 *A. versicolor*                                            SK-MEL-2 (skin) XF498 (CNS) HCT15 (Colon)                                                                                                   0.67 μM 0.14 μM 0.13 μM                                         Lee et al., [@B70]
  81\.                Cordyheptapeptides C--E **(225--227)**                                                                       Cyclo heptapeptide          *Acremonium persicinum*                                    SF-268, MCF-7, and NCI-H460                                                                                                                 2.5--12.1 μM                                                    Chen et al., [@B18]
  82\.                Pullularin E and F **(228--229)**                                                                            --                          *Bionectria ochroleuca*                                    L5178Y (lymphoma)                                                                                                                           0.1 and 6.7 μg/mL                                               Ebrahim et al., [@B27]
  83\.                Clavatustides A--C **(230--232)**                                                                            Cyclodepsipeptide           *Aspergillus clavatus*                                     Hepatocellular Carcinoma Cycle Inhibitory                                                                                                   --                                                              Jiang et al., [@B57]; Ye et al., [@B181]
  84\.                Asperterrestide A **(233)**                                                                                  Cyclic tetrapeptide         *Aspergillus terreus*                                      U937 (carcinoma) and MOLT4 cell                                                                                                             6.4 and 6.2 μM                                                  He et al., [@B48]
  85\.                Similanamide **(234)**                                                                                       Cyclohexapeptide            *Aspergillus similanensis*                                 MCF-7 (breast), NCI-H460 (lung) and A373 (melanoma)                                                                                         125 ± 0 117.50 ± 3.55 115 ± 7.07                                Prompanya et al., [@B132]

###### 

NRPs with both antimicrobial and anticancer potential from marine microbes.

  **Sr. No**.   **NRPs**                                                           **Chemical architecture**                **Source**                          **Biological target**                                                              **Biological active value (MIC/IC~50~/GI~50~/ID~50~/ED~50~)**   **References**
  ------------- ------------------------------------------------------------------ ---------------------------------------- ----------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------- -----------------------------
  1\.           Lajollamycin **(235)**                                             Spiro-β-lactone-γ-lactam                 *Streptomyces nodosus*              Drug resistant gram-positive bacteria/                                             2--20 μg/mL                                                     Manam et al., [@B86]
                murine melanoma cell line B16-F10                                  EC~50~ of 9.6 μM                                                                                                                                                                                                                
  2\.           Ariakemicins A-B **(236-237)**                                     Linear peptide                           *Rapidithrix* sp                    *S. aureus/*                                                                       0.46 μg/mL                                                      Oku et al., [@B120]
                human lung cancer cells (A549) and baby hamster kidney cells       IC~50~ values of 25 and 15 μg/mL                                                                                                                                                                                                
  3\.           Ieodoglucomide A-B **(238-239)**                                   Glycolipopeptide                         *Bacillus licheniformis*            Antibacterial/lung cancer and stomach cancer cell lines                            GI~50~ values of 25.18 and 17.78 μg/mL                          Tareq et al., [@B158]
  4\.           Halolitoralin A **(240)** Halolitoralins B **(241)** C **(242)**   Cyclic hexapeptide Cyclic tetrapeptide   *Halobacillus litoralis*            *Candida albicans* and *Tricophyton rubrum*/human gastric tumor                    20, 30, 30 μg/mL and 25, 35, 40 μg/mL                           Yang et al., [@B180]
  5\.           Mojavensin A **(243)**                                             Lipopeptide                              *Bacillus mojavensis*               *Valsa mali, cucumerinum, and Fusarium verticillioides/*                           2 mg /mL                                                        Ma et al., [@B83]
                HL-60                                                              IC~50~ of 100                                                                                                                                                                                                                   
  6\.           Marthiapeptide A **(244)**                                         Cyclic peptide                           *Marinactinospora thermotolerans*   SF-268 (glioblastoma), MCF-7 (breast), NCI-H460 (lung), HepG2 (hepatocarcinoma)/   0.38--0.52 μM                                                   Zhou et al., [@B188]
                gram-positive bacteria                                                                                                                                                                                                                                                                             
  7\.           Linear heptapeptide **(245)**                                      Heptapeptide                             *Paenibacillus profundus*           SK-MEL-28 cell /                                                                   3.07 μM/                                                        Kalinovskaya et al., [@B61]
                *S. aureus, S. epidermis B. subtilis* and *Enterococcus faecium*   ZOI = 24 mm, 20 mm,28 mm, 11 mm                                                                                                                                                                                                 

NRPs with antimicrobial potential {#s3}
=================================

Antibiotic resistance in bacteria, parasites, viruses and fungi necessitates the continuous discovery of new drugs for the effective prevention and treatment of an ever-increasing range of infections caused by them (Organization, [@B123]). Natural products are the principal source for primary health care. Natural products are observed as a diverse group of molecules which have evolved to interact with a wide variety of protein targets for specific purposes. Also the same protein structure with little or no variation serves different purposes in different organisms. As a result, it is believed that the search for novel antimicrobial entity from natural sources will yield better results than from combinatorial chemistry and other synthetic procedures (Ngwoke et al., [@B114]). Here we described NRPs from marine microbial sources with antimicrobial potential.

Bacteria
--------

A cationic antibiotic Bogorol A **(1)** (Figure [S1](#SM1){ref-type="supplementary-material"}), displaying potent activity against both methicillin-resistant *Staphylococcus aureus* (MRSA, MIC 2 μg/mL) and vancomycin-resistant enterococcal strains (VRE, MIC 10 μg/mL) of bacteria, has been isolated from cultures of a marine *Bacillus laterosporus* collected in Papua New Guinea (Barsby et al., [@B7]). A new broad spectrum thiazolyl peptide antibiotic, Nocathiacins I--III **(2**--**4)** (Figure [S1](#SM1){ref-type="supplementary-material"}), was isolated from the cultured broth of *Nocardia* sp. They share structural similarities to glycothiohexide-alpha (Li et al., [@B74]). All compounds exhibit potent *in vitro* activity against several multiple-drug resistant pathogens with MIC of 0.001--0.015, 0.0005--0.25, 0.002--0.06 μg/mL respectively. They demonstrate excellent *in vivo* efficacy in a systemic *S. aureus* infection mouse model at PD~50~ 0.8, 0.6, 0.6 mg/kg/day respectively (Leet et al., [@B71]). The marine sponge *Halichondria japonica* was the source of *Bacillus cereus* which gave two cyclic thiopeptide antibiotics, YM-266183 **(5)** and YM-266184 **(6)** (Figure [S1](#SM1){ref-type="supplementary-material"}). They exhibited potent antibacterial activity against Staphylococci (MIC 0.05--0.2 μg/mL, 0.013--0.025 μg/mL) and Enterococci including multiple drug resistant strains (MIC 0.02--0.05 μg/mL, 0.006--0.01 μg/mL), whereas, they were inactive against gram-negative bacteria (Nagai et al., [@B111]). These structures contain thiazole and pyridine moieties and several unusual amino acids (Suzumura et al., [@B149]). A bacterial Ruegeria species isolated from a sponge *Suberites domuncula* (Gulf of Naples, Italy), gave two new cyclic peptides, cyclo-(glycyl-l-seryl-l-prolyl-l- glutamyl) **(7)** and cyclo-(glycyl-l-prolyl-l-glutamyl) **(8)** (Figure [S1](#SM1){ref-type="supplementary-material"}) with moderate antimicrobial activity against *Bacillus subtilis* at MIC of 25 and 50 μg/mL, respectively (Mitova et al., [@B104]). *B. laterosporus* PNG276 obtained from Papua New Guinea was the source of a new lipopeptide antibiotic, Tauramamide **(9)** (Figure [S1](#SM1){ref-type="supplementary-material"}). Anti-pathogenic activity against *Enterococcus* sp. were reported for tauramamide and its ethyl ester at MIC 0.1 μg/mL (Desjardine et al., [@B25]). *Pseudomonas* sp. separated out from the seaweed *Diginea* sp. (Ishigaki Is., Okinawa, Japan) were the source of cyclic tetrapeptides cyclo-\[phenylalanyl-prolyl-leucyl-prolyl\] **(10)** and cyclo-\[isoleucyl-prolyl-leucyl-alanyl\] **(11)** (Figure [S1](#SM1){ref-type="supplementary-material"}). The crude extract of this bacterial culture was found to inhibit the growth of other marine bacterial strains (Rungprom et al., [@B138]).

Unnarmicin A **(12)** and C **(13)** (Figure [S2](#SM1){ref-type="supplementary-material"}) are two depsipeptides isolated from a culture of a marine bacterium, *Photobacterium* sp. strain MBIC06485 having selective inhibitory effect on *Pseudovibrio* bacterial strains (Oku et al., [@B121]). A strong antibacterial thiopeptide antibiotic TP-1161 **(14)** (Figure [S2](#SM1){ref-type="supplementary-material"}) with a rare aminoacetone moiety, have been isolated from *Nocardiopsis* sp. MICs value of TP-1161, ranging from 0.25 to 4 μg/ml for most gram-positive strain. The gene cluster for the biosynthesis of **(14)** was identified by PCR screening using degenerate primers (Engelhardt et al., [@B29]). Marine *Photobacterium halotolerant* yielded two novel cyclodepsipeptides Solonamide A **(15)** and B **(16)** (Figure [S2](#SM1){ref-type="supplementary-material"}) with inhibitory effect on virulence gene expression in *S. aureus* (Mansson et al., [@B88]). The fermentation broth of *Streptomyces* strain isolated from a marine sediment sample collected off Nasese, Fiji were the source of three new depsipeptides, Fijimycins A--C **(17--19)** (Figure [S2](#SM1){ref-type="supplementary-material"}). Fijimycins A--C were shown significant activity against three MRSA strains with MIC~100~ values between 4 and 16 μg/mL (Sun et al., [@B147]). Peptidolipins B--F **(20**--**24)** (Figure [S2](#SM1){ref-type="supplementary-material"}), antibacterial lipopeptides were obtained from an ascidian-derived *Nocardia* sp. Peptide **(20)** and **(23)** were moderately antibacterial against MRSA and methicillin-sensitive *S. aureus* (MSSA) (Wyche et al., [@B179]). A marine-derived bacterium *Kocuria palustris* was the source of a new thiazolyl peptide, Kocurin **(25)** (Figure [S2](#SM1){ref-type="supplementary-material"}). Kocurin strongly inhibits MRSA MB5393 with a MIC value of 0.25 μg/mL (Martín et al., [@B90]). An octapeptide, Champacyclin **(26)** (Figure [S2](#SM1){ref-type="supplementary-material"}) was isolated from three strains of *Streptomyces champavatii* (sediment, Gotland Deep and Kiel Bight, Baltic Sea and Urania Basin, Eastern Mediterranean) as an inhibitor of blight disease causing bacterium *Erwinia amylovora* (Pesic et al., [@B126]). Cyclodepsipeptides Ngercheumicin F--I **(27**--**30)** (Figure [S2](#SM1){ref-type="supplementary-material"}) isolated from *P. halotolerans*, inhibited quorum sensing in *S. aureus* (Kjaerulff et al., [@B65]).

Cyanobacteria
-------------

Lobocyclamide B **(31)** (Figure [S3](#SM1){ref-type="supplementary-material"}) a cyclododecapeptide containing five beta-hydroxy-alpha-amino acid residues, was discovered from *Lyngbya confervoides* which was active against fluconazole-resistant *C. albicans*. The absolute stereochemistry was determined by chiral chromatography of Marfey\'s reaction (MacMillan and Molinski, [@B85]). Brunsvicamides A--C **(32**--**34)** (Figure [S3](#SM1){ref-type="supplementary-material"}), three new cyclic hexapeptides have been isolated from cyanobacterium *Tychonema* sp. Brunsvicamide C contains an N-methylated N\'-formylkynurenine moiety. Brunsvicamide B selectively inhibits the *Mycobacterium tuberculosis* protein tyrosine phosphatase B (MptpB, IC~50~ 7.3 μM) (Müller et al., [@B110]).

Fungi
-----

An extraction of a saltwater culture of an unidentifiable sponge-derived fungus leads to discovering two novel cyclic depsipeptides, Guangomides A **(35)** and B **(36)** (Figure [S4](#SM1){ref-type="supplementary-material"}). Both compounds had weak antibacterial activity against *Staphylococcus epidermis* (MIC = 100 μg/mL, each) and *Enterococcus durans* (MIC = 100 μg/mL, each) (Amagata et al., [@B3]). A marine-derived *Aspergillus fumigatus* yielded to 11-O-methylpseurotin A **(37)** (Figure [S4](#SM1){ref-type="supplementary-material"}) (PKS/NRPS), which selectively inhibited a Hof1 deletion strain of the yeast *Saccharomyces cerevisiae* (Boot et al., [@B9]). Marine-derived fungus *Emericella* sp., and marine actinomycete *Salinispora arenicola* were co-cultured to induce production of Emericellamides A **(38)** and B **(39)** (Figure [S4](#SM1){ref-type="supplementary-material"}) by fungi. Emericellamides A and B displayed modest antibacterial activities against MRSA with MIC values of 3.8 and 6.0 μM, respectively (Oh et al., [@B118]).

The fungus *Scopulariopsis brevicaulis*, isolated from marine sponge *Tethya aurantium* was the source of two novel cyclodepsipeptides, Scopularides A **(40)** and B **(41)** (Figure [S4](#SM1){ref-type="supplementary-material"}), which were weak inhibitors of gram-positive bacteria (Yu et al., [@B183]). Alternaramide **(42)** (Figure [S4](#SM1){ref-type="supplementary-material"}), a cyclic Penta depsipeptide, was produced by culture of *Alternaria* sp. which was isolated from sediment, Masan Bay, S. Korea. It\'s showed weak antimicrobial activity against *B. subtilis* (ZOI 8 mm) and *S. aureus* (ZOI 13 mm) (Kim et al., [@B64]). Trichoderins A **(43)**, A1 **(44)**, and B **(45)** (Figure [S4](#SM1){ref-type="supplementary-material"}) are three new amino lipopeptides reported from marine sponge-derived fungus of *Trichoderma* sp. All trichoderins have shown potent anti-mycobacterial activity against *Mycobacterium smegmatis, Mycobacterium bovis* BCG, and *M. tuberculosis* H37Rv under aerobic and dormancy-inducing hypoxic growth conditions with MIC values in the range of 0.02--2.0 l g/mL (Pruksakorn et al., [@B133]).

*Aspergillus* sp. AF119 was the source of γ-aminobutyric acid containing cyclic heptapeptide Unguisin E **(46)** (Figure [S4](#SM1){ref-type="supplementary-material"}) (Liu and Shen, [@B75]). Marine-derived halotolerant *Aspergillus sclerotiorum* PT06-1 gave to two novel cyclic hexapeptides Sclerotides A **(47)** and B **(48)** (Figure [S4](#SM1){ref-type="supplementary-material"}) in a nutrient-limited hypersaline medium. Both of these peptides were photo inter convertible, containing anthranilic acid, dehydroamino acid units and showed moderate antifungal activity against *C. albicans*. Compound **(47)** also inhibited *P. aeruginosa* growth (Zheng et al., [@B186]). A halotolerant *A. sclerotiorum* PT06-1 isolated from salt sediments from the Putian Sea Salt Field, Fujian, China was the source of 11 new aspochracin-type cyclic tripeptides, Sclerotiotides A--K **(49--59)** (Figure [S4](#SM1){ref-type="supplementary-material"}). Only sclerotiotides A, B, F and I showed selective antifungal activity against *C. albicans* with MIC values of 7.5, 3.8, 30, and 6.7 μM, respectively (Zheng et al., [@B185]).

NRPs with anticancer potential {#s4}
==============================

Cancer is the second leading cause of death worldwide. Present therapies cause serious side effects. Therefore there is need to employ alternative concepts including natural products therapy, complementary or alternative medicine, surgery, radiation therapy used alone or in combination to the prevention of cancer (Reddy et al., [@B135]). Here we focus on the marine natural products specially NRPs that have been evaluated for cancer prevention.

Bacteria
--------

Three new cytotoxic cyclopeptides, Mixirins A--C **(60**--**62)** (Figure [S5](#SM1){ref-type="supplementary-material"}) belonging to iturin class have been isolated from marine bacterium *Bacillus* sp. obtained from the mud near the Arctic pole. All compounds inhibited the growth of human colon tumor cells (HCT-116) with IC~50~ of 0.68, 1.6, 1.3 μg/ml. (Zhang et al., [@B184]). A *Thermoactinomyces* specie YM3-251 have been isolated from mud (Mecherchar, Republic of Palau), which was the source of a cyclic peptide Mechercharmycin A **(63)** as well as the linear congener Mechercharmycin B **(64)** (Figure [S5](#SM1){ref-type="supplementary-material"}). Mechercharmycin A exhibited relatively strong antitumor activity against A549 cells (human lung cancer) and Jurkat cells (human leukemia) with IC~50~ value of 4.0 × 10^−8^ M and 4.6 × 10^−8^ M respectively, whereas mechercharmycin B exhibited no activity (Kanoh et al., [@B62]). Bromoalterochromides A and A\' **(65--66)** (Figure [S5](#SM1){ref-type="supplementary-material"}), an unprecedented chromo peptide was produced by a marine *Pseudoalteromonas maricaloris* strain KMM 636 which was isolated from sponge *Fascaplysinopsis reticulata*. Chemically both of these compounds are brominated yellow colored Thr-Val-Asn-Asn-X pentapeptide lactones, where the amino group of Thr is acylated with 9-(3-bromo-4-hydroxyphenyl)-nona-2, 4,6,8-tetraenoic acid, and X is aIle and Leu, respectively. They showed moderate cytotoxic effects on developing eggs of the sea urchin *Strongylocentrotus intermedius* (Speitling et al., [@B145]). New 3-methyl-4-ethylideneproline-containing cytotoxic peptides, Lucentamycins A--D **(67--70)** (Figures S5, S6) have been isolated from the broth of a marine-derived actinomycete *Nocardiopsis lucentensis* (strain CNR-712). Only lucentamycins A and B showed significant *in vitro* cytotoxicity against HCT-116 human colon carcinoma with IC~50~ values of 0.20 and 11 μM, respectively (Cho et al., [@B19]).

Three cyclic hexadepsipeptides Piperazimycins A--C **(71**--**73)** (Figure [S6](#SM1){ref-type="supplementary-material"}) have been isolated from the fermentation broth of a *Streptomyces* sp. (sediment, Guam). The structures of these cyclic hexadepsipeptides have shown presence of rare amino acids, including hydroxyacetic acid, α-methylserine, γ-hydroxypiperazic acid, γ-chloropiperazic acid 2-amino-8-methyl-4, 6-nonadienoic acid, and 2-amino-8-methyl-4,6-decadienoic acid and were all significantly cytotoxic against multiple tumor cell lines with an average GI~50~ 76 ng/mL for each (Miller et al., [@B102]). The cultured mycelia of marine bacterium *Mechercharimyces asporophorigenens* (marine lake sediment, Urukthapel Island, Palau) was the source of Urukthapelstatin A **(74)** (Figure [S6](#SM1){ref-type="supplementary-material"}), a cyclic thiopeptide that displayed potent activity against a human cancer cell line panel. Urukthapelstatin A has also shown growth inhibition of human lung cancer A549 cells in dose-dependent manner with an IC value of 12 nM (Matsuo et al., [@B93]). The culture of *Salinispora arenicola* isolated from sea sediment (Great Astrolabe Reef, Fijiy) yielded three new cyclohexadepsipeptides, Arenamides A--C **(75**--**77)** (Figure [S6](#SM1){ref-type="supplementary-material"}). The absolute structures and configuration of these compounds were established by the spectroscopic technique. Arenamides A **(75)** and B **(76)** blocked tumor necrosis factor (TNF)-induced activation with IC~50~ values of 3.7 and 1.7 μM respectively. In addition, they also inhibited nitric oxide and prostaglandin E2 production and were moderately cytotoxic to HCT-116 cells (Asolkar et al., [@B5]). *Bacillus silvestris* that was isolated from a Pacific Ocean (southern Chile) crab yields two new cyclodepsipeptides, Bacillistatins 1-2 **(78**--**79)** (Figure [S6](#SM1){ref-type="supplementary-material"}) with strong anti-cancer (GI~50~ of 10^−4^-10^−5^ μg/mL) activity (Pettit et al., [@B128]). The epimeric cyclic peptides Turnagainolides A **(80)** and B **(81)** (Figure [S6](#SM1){ref-type="supplementary-material"}), isolated from marine *Bacillus* sp. (sediment, Turnagain Is., British Columbia, Canada), had indirect inhibitory effect on phosphatidylinositol-3-kinase (PI3K) pathway (Li et al., [@B73]). A *Streptomyces* sp. obtained from marine sediment produced two highly modified linear tetrapeptides, Padanamides A **(82)**, and B **(83)** (Figure [S6](#SM1){ref-type="supplementary-material"}). They inhibit cysteine and methionine biosynthesis and are cytotoxic to Jurkat cells (IC~50~ of 20 μg/mL) respectively (Williams et al., [@B170]). Chemical genomics was performed to discover the mode of action of compounds, which suggested that padanamide A inhibits cysteine and methionine biosynthesis.

*Streptomyces* sp. isolated from volcanic island produced new cyclic peptides Ohmyungsamycin A **(84)** and B **(85)** (Figure [S7](#SM1){ref-type="supplementary-material"}). The presence of unusual amino acid units, including N-methyl-4-methoxytrytophan, β-hydroxyphenylalanine, and N, N-dimethylvaline in compound **(84--85)** have been determined by interpretation of the NMR, UV, and IR spectroscopic and MS data. Both exhibited inhibitory activities against diverse cancer cells with IC~50~ values ranging from 359 to 816 nM and 12.4 to 16.8 μM respectively. However, compound **(84)** was more active in this regard interestingly; these compounds exhibit relatively selective anti-proliferative activity against cancer cells compared to normal cells. This may be due to the consequence of genetic background or of the biologically various characteristics between cancer and normal cells. However, the exact molecular mechanism behind the selectivity should be further investigated (Um et al., [@B166]). Proximicins A--C **(86**--**88)** (Figure [S7](#SM1){ref-type="supplementary-material"}) are novel aminofuran antibiotics with anticancer activity, isolated from marine strains of *verrucosispora* sp. Compounds **(86--88)** showed inhibitory activity against gastric adenocarcinoma (AGS, IG~50~ = 0.6, 1.5, 0.25 μg/mL respectively), hepatocellular carcinoma (HepG2, IG~50~ = 0.8, 9.5, 0.7 μg/mL respectively) and breast carcinoma cells (MCF 7, IG~50~ = 7.2, 5.0, 9.0 μg/mL respectively). A cell-cycle analysis in AGS cells revealed that Proximicin C produced cell arrest in the G0/G1 phase after incubation for 24 h. After 40 h, there was an increase in the number of cells in the sub-G1 phase, that is, apoptotic cells (+2.9%). It was also found that proximicin C induce upregulation of p53 and of the cyclin kinase inhibitor p21 in AGS cells (Fiedler et al., [@B33]).

Cyanobacteria
-------------

An assemblage of *Lyngbya majuscula* and *Phormidium gracile* collected in Papua New Guinea produced a cyclic depsipeptide Hoiamide A **(89)** (Figure [S8](#SM1){ref-type="supplementary-material"}). The highly unusual structure of hoiamide A synthesized by mixed peptide--polyketide biosynthetic pathway showed moderate cytotoxicity to cancer cells and partial agonist of site 2 on the voltage-gated sodium channel as it produced a rapid and concentration-dependent elevation of neuronal \[Na^+^\] in neocortical neurons (IC~50~ = 92.8 nM) (Pereira et al., [@B125]). An assemblage of the marine cyanobacteria *L. majuscula* and *Schizothrix* species collected from Fiji was the source of cyclic depsipeptides Yanucamides A **(90)** and B **(91)** (Figure [S8](#SM1){ref-type="supplementary-material"}), which contain a 2, 2-dimethyl-3-hydroxyoct-7-ynoic acid moiety. Both compounds exhibited strong brine shrimp toxicity (LD~50~, 5 ppm) (Sitachitta et al., [@B144]). The cyclic depsipeptides named Lyngbyabellins A **(92)** (Figure [S8](#SM1){ref-type="supplementary-material"}), contain a 7,7-dichloro-2,2-dimethyl-3-hydroxyoctanoic acid moiety have been isolated from the cytotoxic fraction of *L. majuscula* collected from Guam and the Dry Tortugas National Park, Florida. Compound **(92)** have moderate cytotoxicity against human nasopharyngeal carcinoma cell line (KB cells) and human colon adenocarcinoma cell line (LoVo cells), with IC~50~ values of 0.03 and 0.50 μg/mL, respectively and also showed cellular microfilament network in A-10 cells at 0.01--5.0 μg/mL concentrations (Luesch et al., [@B81]). Another collection from Tortugas National Park, Florida was the source of cytotoxic and antifungal cyclic depsipeptide Lyngbyabellin B **(93)** (Figure [S8](#SM1){ref-type="supplementary-material"}). Lyngbyabellin B was toxic to brine shrimp (LD~50~ = 3.0 ppm) (Milligan et al., [@B103]). A marine cyanobacterium *Microcystis aeruginosa* contained the cyclic hexapeptide Microcyclamide **(94)** (Figure [S8](#SM1){ref-type="supplementary-material"}), which showed moderate cytotoxicity against P388 murine leukemia cells at 24--30 μg/mL (Ishida et al., [@B56]).

The cyanobacterium *L. majuscule* collected from Guam was the source of Apratoxin A **(95)** (Figure [S8](#SM1){ref-type="supplementary-material"}). This cyclodepsipeptide of mixed peptide-polyketide biogenesis exhibited *in vitro* cytotoxicity against human tumor cell lines at IC~50~ of 0.36--0.52 nM. Apratoxin A induces G1 phase cell arrest and apoptosis, which is at least particularly initiated through antagonism of FGF signaling via STAT3 (Luesch et al., [@B80]). Another collection of *L. majuscule* from Guam gave two cyclic depsipeptides, Pitipeptolides A **(96)** and B **(97)** (Figure [S8](#SM1){ref-type="supplementary-material"}) with anti-mycobacterial and weak cytotoxicity against LoVo cells with IC~50~ values of 2.25 and 1.95 μg/mL, respectively. Pitipeptolides A and B also stimulated elastase activity. It is suggested that this activity is due to the presence of hydrophobic portions in the molecule (Luesch et al., [@B78]). Marine cyanobacterium *Lyngbya* sp. collected from Palauan was the source of six new β-amino acid-containing cyclic depsipeptides, the Ulongamides A--F **(98**--**103)** (Figure [S8](#SM1){ref-type="supplementary-material"}). All peptides were found to be weakly cytotoxic against KB and LoVo cells with IC~50~ values of ca. 1 μM and ca. 5 μM respectively except compound Ulongamides F (Luesch et al., [@B79]). Examination of a *L. confervoides* collection from Saipan, Commonwealth of the Northern Mariana Islands, led to the isolation of a novel cytotoxic cyclic depsipeptide Obyanamide **(104)** (Figure [S8](#SM1){ref-type="supplementary-material"}). Obyanamide was cytotoxic against KB cells with an IC~50~ of 0.58 μg/mL. According to the results, the β-amino acid residue was found to play a critical role in the biological activities. Additionally, the ester bond along with the Ala (Thz) moiety was also essential for biological activities (Williams et al., [@B172]). Malevamide D **(105)** (Figure [S8](#SM1){ref-type="supplementary-material"}), a highly cytotoxic peptide ester have been isolated from marine cyanobacterium *Symploca hydnoides* (Horgen et al., [@B50]). A culture *Symploca* sp. yielded Tasiamide **(106)** (Figure [S8](#SM1){ref-type="supplementary-material"}), an acyclic peptide. Tasiamide demonstrated cytotoxic activity against KB and LoVo cells with IC~50~ values of 0.48 and 3.47 μg/mL, respectively (Williams et al., [@B173]). A new cytotoxic peptide Tasiamide B **(107)** (Figure [S9](#SM1){ref-type="supplementary-material"}) which contain the unusual amino acid-derived residue 4-amino-3-hydroxy-5-phenylpentanoic acid (Ahppa) have been isolated from cyanobacterium *Symploca* sp. This peptide displayed an IC~50~ value of 0.8 μM against KB cells (Williams et al., [@B174]).

A Papua New Guinea collection of the marine cyanobacterium *L. majuscule* was the source of six cyclic depsipeptides, Guineamides A--F **(108**--**113)** (Figure [S9](#SM1){ref-type="supplementary-material"}). The presence of beta-amino or beta-hydroxy carboxylic acid residues in all peptides was determined using a combination of chemical manipulations as well as Marfey\'s method. Guineamides B and C showed moderate cytotoxicty to a mouse neuroblastoma cell line with IC~50~ values of 15 and 16 μM, respectively (Tan et al., [@B152]). A new bioactive cyclic depsipeptide, Homodolastatin 16 **(114)** (Figure [S9](#SM1){ref-type="supplementary-material"}) have been isolated from *L. majuscula*, collected from Wasini Island off the southern Kenyan coast. Homodolastatin 16 showed moderate activity against oesophageal (IC~50~ = 4.3 μg/mL) and cervical cancer cell lines (IC~50~ = 1 μg/mL) (Davies-Coleman et al., [@B24]). An examination of an organic extract of a cyanobacterium *L. majuscula*, collected from Guam, led to the isolation of the cyclic peptide Lyngbyastatin 3 **(115)** (Figure [S9](#SM1){ref-type="supplementary-material"}). The presence of two unusual amino acid units, 3-amino-2-methylhexanoic acid (Amha) and 4-amino-2, 2-dimethyl-3-oxopentanoic acid units (Ibu) was determined by standard methods. Lyngbyastatin 3 displayed *in vitro* activity against KB and LoVo cell lines with IC~50~ values of 32 and 400 nM respectively (Williams et al., [@B171]).

A collection of *Lyngbya* sp. from Palauan was the source of cytotoxic cyclic depsipeptide Ulongapeptin **(116)** (Figure [S9](#SM1){ref-type="supplementary-material"}) with an IC~50~ value of 0.63 μM against KB cells (Williams et al., [@B176]). Two new depsipeptides Tasipeptins A **(117)** and B **(118)** (Figure [S9](#SM1){ref-type="supplementary-material"}) have been isolated from Palau collection of *Symploca* sp. The gross structure of all peptides **(117--118)** were determined by standard methods and was found to contain unusual amino acid-derived residue 4-amino-3-hydroxy-5-phenylpentanoic acid (Ahppa) and 3-amino-6-hydroxy-2-piperidone (Ahp) moiety respectively. Both were cytotoxic toward KB cells with IC~50~ values of 0.93 and 0.82 μM, respectively (Williams et al., [@B175]). *Lyngbya majuscula* collected from Hector\'s Bay, Jamaica was found to contain three lipopeptides, Jamaicamides A--C **(119**--**121)** (Figure [S9](#SM1){ref-type="supplementary-material"}). Further biological investigation of the jamaicamides has revealed that they are generated by iterative hybrid PKS-NRPS assembly and exhibited cytotoxicity to both the H-460 human lung and Neuro-2a mouse neuroblastoma cell lines (IC~50~ = 15 μM for all), sodium channel blocking activity at 5 μM and ichthyotoxic activities (Edwards et al., [@B28]). Four new depsipeptides, Wewakpeptins A--D **(122**--**125)** (Figures [S9](#SM1){ref-type="supplementary-material"}, [S10](#SM1){ref-type="supplementary-material"}), were found cytotoxic to brine shrimp and to the NCI-H460 and neuro-2a cell lines (LC~50~ of approximately 0.4 μM). These were isolated from *Lyngbya semiplena* collected from Wewak Bay, Papua New Guinea (Han et al., [@B44]).

Trungapeptins A-C **(126**--**128)** (Figure [S10](#SM1){ref-type="supplementary-material"}), cyclodepsipeptides have been isolated from marine cyanobacterium *L. majuscula*. Trungapeptin A exhibited mild icthyotoxicity (6.25 ppm) and weak toxicity to brine shrimp (10 ppm) (Bunyajetpong et al., [@B12]). Cytotoxic cyclic peptides, Aurilides B **(129)** and C **(130)** (Figure [S10](#SM1){ref-type="supplementary-material"}) were produced by marine cyanobacterium *L. majuscula* collected from Papua New Guinea. Both aurilides B and C described to induce a dysfunction in mitochondria in NCI-H460 human lung tumor and the neuro-2a mouse neuroblastoma cell lines, with LC~50~ values between 0.01 and 0.13 μM (Han et al., [@B45]). A highly methylated tetrapeptide Belamide A **(131)** (Figure [S10](#SM1){ref-type="supplementary-material"}) was isolated from *Symploca* sp. (Salmedina Reef, Panama) which was shown antimitotic and cytotoxic to MCF7 breast cancer and HCT-116 cell lines (IC~50~ 0.74 μM) by microtubule disruption with structural analogy to the important linear peptides dolastatins 10 and 15 (Simmons et al., [@B142]). Three new analogs of dolastatin 13, Lyngbyastatins 5-7 **(132--134)** (Figure [S10](#SM1){ref-type="supplementary-material"}), have been isolated from two different collections of marine cyanobacteria, *Lyngbya* sp., from South Florida with previously reported cyclodepsipeptide somamide B. Compounds (**132**--**134**) were found to selectively inhibit elastase over several other serine proteases, with IC~50~ values for porcine pancreatic elastase ranging from 3 to 10 nM (Taori et al., [@B157]). A new linear peptide Mitsoamide **(135)** (Figure [S10](#SM1){ref-type="supplementary-material"}) was produced by marine cyanobacterium *Geitlerinema* sp. collected from Mitso-Ankaraha Island. Mitsoamide has shown strong activity against NCI-H460 human lung tumor cells with LC~50~ of 460 nM (Andrianasolo et al., [@B4]).

A Papua New Guinea collection of the marine cyanobacteria *L. majuscula* and *Lyngbya sordida* was the source of potent cytotoxic cyclodepsipeptide Apratoxin D **(136)** (Figure [S10](#SM1){ref-type="supplementary-material"}). Compound **(136)** possesses 3, 7-dihydroxy-2, 5, 8, 10, 10-pentamethylundecanoic acid as the polyketide moiety and potent *in vitro* cytotoxicity against H-460 human lung cancer cells with an IC~50~ value of 2.6 nM (Gutiérrez et al., [@B43]). Another collection of marine cyanobacterium *Lyngbya bouillonii* from a Guamanian was found to contain Apratoxin E **(137)** (Figure [S10](#SM1){ref-type="supplementary-material"}), which was strongly cytotoxic to several cancer cell lines at IC~50~ 21--72 nM (Matthew et al., [@B95]). Dragonamides C **(138)** and D **(139)** (Figures [S10](#SM1){ref-type="supplementary-material"}, [S11](#SM1){ref-type="supplementary-material"}) are linear lipopeptides isolated from the marine cyanobacterium brown *Lyngbya polychroa*. Both peptides are weak cytotoxic against several cancer cell lines with GI~50~ values of 56 and 59 μM against U2OS osteosarcoma cells, 22 and 32 μM against HT29 colon adenocarcinoma cells, and 49 and 51 μM against IMR-32 neuroblastoma cells, respectively (Gunasekera et al., [@B42]). Coibamide A **(140)** (Figure [S11](#SM1){ref-type="supplementary-material"}), a potent anti-proliferative highly methylated cyclic depsipeptide was isolated from a culture of *Leptolyngbya* sp. which was collected from the Coiba National Park, Panama. Compound **(140)** showed an unprecedented selectivity profile in the NCI 60 cancer cell line panel (LC~50~ \< 23 nM). It causes S phase inhibition in cell cycle (Medina et al., [@B98]). *Symploca* sp. yielded dolastatin 10/15 hybrid linear peptide Symplostatin 4 **(141)** (Figure [S11](#SM1){ref-type="supplementary-material"}) which was shown to be antimitotic activity via microtubule depolymerization to H-460 lung cancer cells (IC~50~ = 40 nM) as well as neuro-2a neuroblastoma cells (IC~50~ = 29 nM) (Taori et al., [@B156]).

A culture of *L. majuscule* obtained from True Blue Bay, eastern Caribbean yielded two new depsipeptides, Itralamides A **(142)** and B **(143)** (Figure [S11](#SM1){ref-type="supplementary-material"}). Only itralamide B was found to cytotoxic to HEK293 cells IC~50~ 6 ± 1 μM (Jiménez et al., [@B58]). An active peptide metabolite Desmethoxymajusculamide C **(144)** (Figure [S11](#SM1){ref-type="supplementary-material"}) (DMMC) have been isolated from Fijian collection of *L. majuscule*. Both cyclic and liner version of DMMC were found potent and showed selective anti-solid tumor activity at IC~50~ = 20 nM against HCT-116 through disruption of cellular microfilament networks (Simmons et al., [@B143]). A Singapore collection of *L. majuscule* has been shown to produce cyclodepsipeptide, Hantupeptin A **(145)** (Figure [S11](#SM1){ref-type="supplementary-material"}) with cytotoxicity to MOLT-4 leukemia cells (IC~50~ 32 μM) and MCF-7 breast cancer cells (IC~50~ 4.0 μM) (Tripathi et al., [@B162]). Chemical investigation of *Lyngbya cf. polychroa* resulted in isolation of a linear peptide desacetylmicrocolin B **(146)** (Figure [S11](#SM1){ref-type="supplementary-material"}), was a growth inhibitor of HT-29 (IC~50~ 14 nM) and IMR-32 cells (IC~50~ 14 nM) (Meickle et al., [@B100]).

Palmyramide A **(147)** (Figure [S11](#SM1){ref-type="supplementary-material"}), a cyclic depsipeptide found to block sodium channel in neuro-2a cells (IC~50~ 17.2 μM) and modest cytotoxicity to H-460 cells (IC~50~ 39.7 μM) and was isolated from from a Palmyra Atoll Collection of the marine cyanobacterium *L. majuscule* (Taniguchi et al., [@B155]). *Lyngbya* sp. was the source of a potent cytotoxic peptide Bisebromoamide **(148)** (Figure [S11](#SM1){ref-type="supplementary-material"}) which potentially inhibit protein kinase and is cytotoxic to HeLa S3 cells with an IC~50~ value of 0.04 μg/mL (Teruya et al., [@B159]). An examination of an organic extract of the cyanobacterium *L. bouillonii*, collected from Guam, led to the isolation of cytoskeletal actin-disrupting and cytotoxic (IC~50~ = 0.041 μM) Lyngbyabellin J **(149)** and a linear modified peptide, lyngbyapeptin D **(150)** (Figure [S11](#SM1){ref-type="supplementary-material"}) (Matthew et al., [@B94]). Marine cyanobacterium *L. confervoides* gave bis-thiazoline containing cyclic depsipeptides, Grassypeptolides A--C **(151-153)** (Figure [S12](#SM1){ref-type="supplementary-material"}). All grassypeptolides cause G1 phase cell cycle arrest in HT29 (IC~50~ = 1.22, 4.97 μM, 76.7 nM) and HeLa cell lines (IC~50~ = 1.01, 2.93 μM, 44.6 nM) (Kwan et al., [@B69]). Hantupeptins B **(154)** and C **(155)** (Figure [S12](#SM1){ref-type="supplementary-material"}), two cytotoxic cyclodepsipeptides were obtained from a marine cyanobacterium *L. majuscule* collected from Pulau Hantu Besar, Singapore. Compound **(154)** gave an IC~50~ of 0.2 μM against MOLT-4 and 0.5 μM against MCF-7 cancer cell lines however compound **(155)** showed moderate cytotoxicity against the MOLT-4 and MCF-7 cancer cell lines with IC~50~ values of 3.0 μM and 1.0 μM, respectively (Tripathi et al., [@B163]). Marine cyanobacteria *Lyngbya* sp. was the source of novel cyclic peptides Lyngbyacyclamides A **(156)** and B **(157)** (Figure [S12](#SM1){ref-type="supplementary-material"}) which moderately inhibited the growth of B16 mouse melanoma cells (IC~50~ of 0.7 μM) (Maru et al., [@B91]).

The marine cyanobacterium *Leptolyngbya* sp. collected from the SS Thistlegorm shipwreck in the Red Sea offered two cyclic depsipeptides, Grassypeptolides D **(158)** and E **(159)** (Figure [S12](#SM1){ref-type="supplementary-material"}). Both of these peptides were cytotoxic to HeLa (IC~50~ = 335 and 192 nM, respectively) and mouse neuro-2a blastoma cells (IC~50~ = 599 and 407 nM, respectively) (Thornburg et al., [@B161]). Bis-thiazoline-containing cyclic depsipeptides Grassypeptolides F **(160)** and G **(161)** (Figure [S12](#SM1){ref-type="supplementary-material"}) which contains rare β-amino acid, extensive N-methylation and a large number of d-amino acids was isolated from an extract of Palauan cyanobacterium *L. majuscule*. Both **(160)** and **(161)** were found to have moderate inhibitory activity against the transcription factor AP-1 (IC~50~ = 5.2 and 6.0 μM, respectively) (Popplewell et al., [@B130]). An examination of an organic extract of the cyanobacterium *Symploca cf. hydnoides* sampled from Cetti Bay, Guam, led to the isolation of the eleven new peptides Veraguamides A-G **(162--168)**, Veraguamide H **(169)** and J--L **(170--172)** (Figure [S12](#SM1){ref-type="supplementary-material"}). Veraguamide A showed potent cytotoxicity to H-460 human lung cancer cell line at LD~50~ = 141 nM whilst the others were weak inhibitors. Their structures were elucidated by combining various techniques in spectroscopy, chromatography, and synthetic chemistry (Mevers et al., [@B101]; Salvador et al., [@B139]).

Three new cyclic peptides Malyngamide 3 **(173)** and Cocosamides A **(174)** and B **(175)** (Figure [S13](#SM1){ref-type="supplementary-material"}) have been isolated from the lipophilic extract of marine cyanobacteria *L. majuscula* collected from Cocos Lagoon, Guam and were found to modestly cytotoxic to HT-29 cells with IC~50~ value of 48, 24, and 11 μM respectively (Gunasekera et al., [@B41]). *L. majuscula* (Piti Bomb Holes, Guam) was the source of proline rich unusual cyclic depsipeptide Pitiprolamide **(176)** (Figure [S13](#SM1){ref-type="supplementary-material"}). Further investigation yielded four more peptides Pitipeptolides C--F **(177--180)** (Figure [S13](#SM1){ref-type="supplementary-material"}). All peptides were found moderately cytotoxic against two HTCLs, however, pitipeptolides C--F were more active against *M. tuberculosis* and *B. cereus* as compared to compound **(176)** (Montaser et al., [@B107]). The marine cyanobacterium *L. majuscule* collected from western lagoon of Pulau Hantu Besar, Singapore was the source of cyclodepsipeptide Lagunamide C **(181)** (Figure [S13](#SM1){ref-type="supplementary-material"}). Lagunamide C exhibited potent cytotoxic activity against HTCLs with IC~50~ values ranging from 2.1 to 24.4 nM, antimalarial activity against *Plasmodium falciparum* (IC~50~ 0.29 μM) and weak anti-swarming activity against *P. aeruginosa* (Tripathi et al., [@B164]).

A collection of marine cyanobacterium *L. semiplena* and *L. majuscule* from Papua New Guinea led to isolation of the cyclic depsipeptides Wewakamide A **(182)** and Guineamide G **(183)** (Figure [S13](#SM1){ref-type="supplementary-material"}) were respectively. Both of these peptides displayed potent toxicity against brine shrimp and only guineamide G showed cytotoxicity to a mouse neuroblastoma cell line with LC~50~ values of 2.7 μM (Nan et al., [@B112]). A *Lyngbya* sp. collected in Florida Keys was found to contain epimeric cyclic depsipeptides Porpoisamide A **(184)** and B **(185)** (Figure [S13](#SM1){ref-type="supplementary-material"}) which was weakly cytotoxic to HCT-116 (IC~50~ = 25, 21 μM respectively) and osteosarcoma U2OS cells (IC~50~ = 28, 22 μM respectively) (Meickle et al., [@B99]). *Moorea bouillonii* (Strawn Is., Palmyra Atoll, Central Pacific Ocean) gave five lipopeptides Lyngbyabellin K **(186)** and L **(187)**, 7-epi-lyngbyabellin L **(188)** and Lyngbyabellin M **(189)** and N **(190)** (Figure [S13](#SM1){ref-type="supplementary-material"}). Of note, cyclic metabolites **(189)** and **(190)** possess rare monochlorination on the 3-acyloxy-2-methyloctanoate residue, whereas unusual N, N-dimethylvaline containing lyngbyabellin N was strongly cytotoxic to HCT116 colon cancer cell line (IC~50~ = 40.9 ± 3.3 nM) (Choi et al., [@B20]). Viequeamides are novel 2, 2-dimethyl-3-hydroxy-7-octynoic acid (Dhoya)-containing cyclic depsipeptides isolated from a shallow subtidal collection of a "button" cyanobacterium *Rivularia* sp. (Vieques, Puerto Rico). The absolute structures and configurations of major components Viequeamide A-D **(191--194)** (Figures [S13](#SM1){ref-type="supplementary-material"}, [S14](#SM1){ref-type="supplementary-material"}) of the mixture were established by spectroscopic technique. However, viequeamides B--F were not separated out and only viequeamide A showed high cytotoxicity against H460 human lung cancer cells at IC~50~ 60 ± 10 nM (Boudreau et al., [@B10]). A new N, N-dimethyl-terminated linear peptide Symplocin A **(195)** (Figure [S14](#SM1){ref-type="supplementary-material"}) was produced by Bahamian collection of cyanobacterium *Symploca* sp. The absolute configuration of symplocin A was done by chiral-phase HPLC of the corresponding 2-naphthacyl esters. Symplocin A showed potent inhibitory effect on protease enzyme cathepsin E with IC~50~ 300 pM (Molinski et al., [@B106]). A collection of tropical marine cyanobacterium, *M. bouillonii*, from New Britain, Papua New Guinea resulted in isolation of a novel cytotoxic cyclic depsipeptide, Bouillonamide **(196)** (Figure [S14](#SM1){ref-type="supplementary-material"}). Compound **(196)** which contains two unique polyketide-derived moieties, a 2-methyl-6-methylamino-hex-5-enoic acid residue and a unit of 3-methyl-5-hydroxy-heptanoic acid have shown mild toxicity against neuron 2a mouse neuroblastoma cells with IC~50~ 6.0 μM (Tan et al., [@B151]). A new lipopeptides, Malyngamide 4 **(197)** (Figure [S14](#SM1){ref-type="supplementary-material"}) as a moderate inhibitor of several HTCLs have been isolated from marine cyanobacterium *Moorea producens* collected from the Red Sea, Saudi Arabia (Shaala et al., [@B140]). The marine cyanobacterium *Okeania* sp. collected from the coast near Jahana, Okinawa, was the source of Kurahyne B **(198)** (Figure [S14](#SM1){ref-type="supplementary-material"}). It showed growth inhibition against HeLa and HL60 cells, with IC~50~ values of 8.1 and 9.0 μM, respectively (Okamoto et al., [@B119]).

Fungi
-----

A culture of marine fungi *Fusarium* CNL-619 was the source of a new cyclic depsipeptide N-Methylsansalvamide **(199)** (Figure [S15](#SM1){ref-type="supplementary-material"}), which showed weak *in vitro* cytotoxicity against NCI human tumor cell lines (GI~50~ 8.3 μM) (Cueto et al., [@B23]). An unidentified fungus isolated from the red alga, *Ceradictyon spongiosum* (Okinawa) have been shown to produce two linear dodecapeptides, Dictyonamides A **(200)** and B **(201)** (Figure [S15](#SM1){ref-type="supplementary-material"}). Only the compound **(200)** showed inhibitory effect on cyclin-dependent kinase 4 with IC~50~ value of 16.5 μg/mL (Komatsu et al., [@B66]). A culture of marine fungus, *Scytalidium* sp., collected from Bahamas was the source of two new cyclic heptapeptides Scytalidamides A **(202)** and B **(203)** (Figure [S15](#SM1){ref-type="supplementary-material"}) and both compounds displayed moderate cytotoxicity to the HCT-116 cell line *in vitro* with IC~50~ values of 2.7 and 11.0 μM, respectively (Tan et al., [@B150]). A strain of *Trichoderma virens* was isolated from ascidian *Didemnum molle* and from the surface of a green alga of genus *Halimeda* from Papua New Guinea, which was the source of two modified dipeptides Trichodermamides A **(204)** and B **(205)** (Figure [S15](#SM1){ref-type="supplementary-material"}). Trichodermamide B has showed significant *in vitro* cytotoxicity against HCT-116 cells (colon carcinoma) with an IC~50~ of 0.32 μg/mL (Garo et al., [@B38]). A fungal strain *Exserohilum rostratum* associated with a marine cyanobacterial mat produced four moderately cytotoxic cyclic dipeptides Rostratins A--D **(206--209)** (Figure [S15](#SM1){ref-type="supplementary-material"}). The structures and absolute configurations of peptides were determined by two-dimensional NMR techniques and Mosher method respectively. Compounds **(206--209)** exhibit activity against colon carcinoma (HCT-116) with IC~50~ values of 8.5, 1.9, 0.76, and 16.5 μg/mL, respectively (Tan et al., [@B153]).

A new cytotoxic cyclodepsipeptide, IB-01212 **(210)** (Figure [S15](#SM1){ref-type="supplementary-material"}) was produced by filamentous fungus *Clonostachys* sp., ESNA-A009 isolated from an unidentified Japanese sponge. IB-01212 was potent cytotoxic to several human tumor cell lines which includes LN-caP (prostrate), SK-BR3 (breast), HT29 (colon), and HELA (cervix) cell lines with GI~50~ (growth inhibition) in order of 10^−8^ M (Cruz et al., [@B22]). A culture of *Zygosporium masonii* isolated from a marine cyanobacterium afforded a new cyclic Penta depsipeptide, Zygosporamide **(211)** (Figure [S15](#SM1){ref-type="supplementary-material"}), which had significant cytotoxicity in the NCI\'s 60 cell line panel, CNS cancer cell line SF-268 (GI~50~ = 6.5 nM) and the renal cancer cell line RXF 393 (GI~50~ ≤ 5.0 nM) (Oh et al., [@B117]). *Trichoderma reesei* isolated from China, Lianyungang collection of sea mud produced moderately cytotoxic Trichoderide A **(212)** (Figure [S15](#SM1){ref-type="supplementary-material"}) (Sun et al., [@B148]). Two new cyclohexadepsipeptides, Spicellamide A **(213)** and Spicellamide B **(214)** (Figure [S15](#SM1){ref-type="supplementary-material"}) obtained from fermentation of *Spicellum roseum* (Ectyplasia perox, Dominica), exhibited cytotoxicity to neuroblastoma cells with IC~50~ value of 30 and 6.2 μg/mL respectively (Kralj et al., [@B67]). Two new cyclic depsipeptides 1962A, cyclo-(d-Leu-Gly-l-Tyr-l-Val-Gly-S-O-Leu) **(215)**, and 1962B, cyclo-(d-Leu-Gly-l-Phe-l-Val-Gly-S-O-Leu) **(216)** (Figure [S15](#SM1){ref-type="supplementary-material"}) have been isolated from the fermentation broth of the mangrove endophytic fungus isolated from the leaf of *Kandelia candel*. Compound **(215)** only showed activity against human breast cancer MCF-7 cells with an IC~50~ value of 100 μg/mL (Huang et al., [@B53]).

Two new cyclic tetrapeptides Microsporins A **(217)** and B **(218)** (Figure [S15](#SM1){ref-type="supplementary-material"}) with potent inhibitors of histone deacetylase (HDAC), cytotoxic to HCT-116 cells (IC~50~ 0.6 and 8.5 μg/mL) was isolated from the marine-derived fungus *Microsporum gypseum* (Gu et al., [@B40]). A Penta decapeptide, Efrapeptin J **(219)** (Figure [S16](#SM1){ref-type="supplementary-material"}), a down-regulator of the molecular chaperone GRP78 have been isolated from *Tolypocladium* sp. (sea mud, *Aomori Prefecture*, Japan) (Hayakawa et al., [@B47]). An Australian marine isolate of *Aspergillus versicolor* (MST-MF495) offered two cyclo pentapeptides, Cotteslosins A **(220)** and B **(221)** (Figure [S16](#SM1){ref-type="supplementary-material"}) (Fremlin et al., [@B36]). Two new cyclic pentapeptides, Versicotides A **(222)** and B **(223)** (Figure [S16](#SM1){ref-type="supplementary-material"}) came from marine fungus strain ZLN-60, identified as *A. versicolor* (Zhou et al., [@B187]). A Cytotoxic lipopeptide Fellutamide F **(224)** (Figure [S16](#SM1){ref-type="supplementary-material"}) have been isolated from the sponge-derived fungus *A. versicolor* with cytotoxicity to several human tumor cells, especially SK-MEL-2 (skin, IC~50~ 0.67 μM), XF498 (CNS, IC~50~ 0.14 μM) and HCT15 (Colon, IC~50~ 0.13 μM) (Lee et al., [@B70]). Fermentation extract of the marine-derived fungus *Acremonium persicinum* SCSIO 115 resulted in the discovery of three new cyclo heptapeptides, Cordyheptapeptides C--E **(225--227)** (Figure [S16](#SM1){ref-type="supplementary-material"}) with cytotoxicity against SF-268, MCF-7, and NCI-H460 tumor cell line with IC~50~ values ranging from 2.5 to 12.1 μM (Chen et al., [@B18]). Chemical investigation of endophytic fungus *Bionectria ochroleuca* isolated from the inner leaf tissues of the plant *Sonneratia caseolaris* (Sonneratiaceae) from Hainan Island (China), lead to discover two new peptides, Pullularins E and F **(228-229)** (Figure [S16](#SM1){ref-type="supplementary-material"}). Both compounds exhibited moderate cytotoxic activity against the mouse lymphoma cells (L5178Y) with EC~50~ values ranging between 0.1 and 6.7 μg/mL (Ebrahim et al., [@B27]). An unusual anthranilic acid dimer and a d-phenyllactic acid residue containing cyclodepsipeptides Clavatustides A--C **(230--232)** (Figure [S16](#SM1){ref-type="supplementary-material"}) were discovered from cultured mycelia and broth of *Aspergillus clavatus* C2WU isolated from *Xenograpsus testudinatus* and suppressed proliferation of HTCLs (Jiang et al., [@B57]; Ye et al., [@B181]). *Aspergillus terreus* SCSGAF0162 gave a new cytotoxic (HTCLs) and antiviral (H1N1 and H3N2) cyclic tetrapeptide, Asperterrestide A **(233)** (Figure [S16](#SM1){ref-type="supplementary-material"}). Which was cytotoxic toward human carcinoma U937 and MOLT4 cell lines with IC~50~ values of 6.4 and 6.2 μM, respectively, and also showed inhibitory effects on the influenza virus strains A/WSN/33 (H1N1) and A/Hong Kong/8/68 (H3N2) with IC~50~ values of 15 and 8.1 μM, respectively (He et al., [@B48]). A new cyclohexapeptide, Similanamide **(234)** (Figure [S16](#SM1){ref-type="supplementary-material"}) was isolated from sponge-associated fungus *Aspergillus similanensis* KUFA 0013 with weak anticancer activity (Prompanya et al., [@B132]).

Marine microorganisms have been recognized as one of the most promising groups of organisms from which novel pharmacologically active molecules, with potential benefits against cancer, can be isolated. Recently, several compounds have been emerged as templates for the development of novel anticancer drugs. However the mechanisms implicated in the cytotoxicity of these compounds in tumor cell lines are still largely overlooked but several studies point to an implication in apoptosis. For instance, several compounds were found to inhibit cell growth in a large variety of cancer cell lines, the pathways by which cancer cells are inhibited are still poorly elucidated. In some cases, compounds were found to induce cell death by activation of the apoptotic process; nevertheless the mechanisms underlying the apoptosis still need more investigations. Some compounds were found to create an imbalance in cellular redox potential, with mitochondria representing a central role in the process. However, more studies are needed in order to clarify it. Cell cycle is another disturbed process, mainly due to disruption of the microtubules and actin filaments; however there are only a few studies connecting marine NRPs with alterations in cell cycle and more studies are needed in order to clarify the involvement of these compounds in the process. Even membrane sodium channels can establish interactions with the compounds, revealing its potentially important role in the observed effects. In summary, more investigations are needed in order to clarify the specific targets and the mechanisms that are behind cancer cell cytotoxicity, namely the involvement of the apoptotic process by the implication of functional genomics.

NRPs with both antimicrobial and anticancer potential {#s5}
=====================================================

Lajollamycin, **(235)** (Figure [S17](#SM1){ref-type="supplementary-material"}) a nitro-tetraene spiro-β-lactone-γ-lactam antibiotic have been isolated from marine actinomycete *Streptomyces nodosus*. *In vitro* lajollamycin inhibited the growth of the murine melanoma cell line B16-F10 with an EC~50~ of 9.6 μM and also displayed antimicrobial activity against both drug resistant and sensitive gram-positive bacteria with MIC 2--20 μg/mL (Manam et al., [@B86]). Two unusual linear hybrid polyketide-nonribosomal peptide antibiotics, Ariakemicins A-B **(236**--**237)** (Figure [S17](#SM1){ref-type="supplementary-material"}) have been isolated from the fermentation broth of the marine gliding bacterium *Rapidithrix* sp., (Ariake Inland Sea, Japan). These antibiotics contain threonine, two omega-amino-(omega-3)-methyl carboxylic acids with diene or triene units, and delta-isovanilloylbutyric acid and selectively inhibited Gram-positive bacteria among which *S. aureus* was the most affected (MIC 0.46 μg/mL) and were slightly cytotoxic to human lung cancer cells (A549) and baby hamster kidney cells with IC~50~ values of 25 and 15 μg/mL respectively (Oku et al., [@B120]). Glycolipopeptides Ieodoglucomide A **(238)** and B **(239)** (Figure [S17](#SM1){ref-type="supplementary-material"}) have been isolated from marine-derived bacterium *Bacillus licheniformis* (sediment, Ieodo Reef, S. Korea). Compounds **(238)** and **(239)** displayed moderately *in vitro* antimicrobial activity. However, ieodoglucomide B also displayed cytotoxic activity against lung cancer and stomach cancer cell lines with GI~50~ values of 25.18 and 17.78 μg/mL, respectively (Tareq et al., [@B158]).

Halolitoralin A (a cyclic hexapeptide) **(240)** (Figure [S17](#SM1){ref-type="supplementary-material"}), Halolitoralin B and C, two cyclic tetrapeptides **(241**--**242)** (Figure [S17](#SM1){ref-type="supplementary-material"}) were isolated from the marine sediment-derived *Halobacillus litoralis* YS3106. All three cyclopeptides show surprisingly simple architectures with highly repeated residue units. Compounds **(241--242)** have shown antifungal activity against two human fungi *Candida albicans* and *Tricophyton rubrum* with MIC of 20, 30, 30 μg/mL and 25, 35, 40 μg/mL respectively. In addition, these three cyclopeptides showed moderate anti-human gastric tumor activities *in vitro* (with a cell line of BGC) (Yang et al., [@B180]). Bioactivity-guided fractionation from the fermentation broth of *Bacillus mojavensis* B0621A (Pearl oyster Pinctada martensii, Weizhou Is., South China Sea) was the source of antifungal iturinic lipopeptide Mojavensin A **(243)** (Figure [S17](#SM1){ref-type="supplementary-material"}). The Marfey\'s analysis of mojavensin A provides the novel peptide backbone of L-Asn1, D-Tyr2, D-Asn3, L-Gln4, L-Pro5, D-Asn6, L-Asn7 and an anteiso-type of the saturated β-fatty acid side chain. Compound 243 also inhibited the growth of HL-60 with IC~50~ of 100 (Ma et al., [@B83]). A new sequential tristhiazole-thiazoline-containing cyclic peptide, Marthiapeptide A **(244)** (Figure [S17](#SM1){ref-type="supplementary-material"}), have been isolated from a culture of the deep South China Sea-derived strain *Marinactinospora thermotolerans* SCSIO 00652. Marthiapeptide A exhibited inhibition against a panel of gram-positive bacteria, with MIC values ranging from 2.0 to 8.0 μg/mL, and displayed strong cytotoxic activity against a panel of human cancer cell lines with IC~50~ values ranging from 0.38 to 0.52 μM (Zhou et al., [@B188]). A new linear glyceryl acid derived heptapeptide (Glyceryl-D-leucyl-D-alanyl-D-leucyl-D-leucyl-L-valyl-D-leucyl-D-alanine, **(245)** (Figure [S17](#SM1){ref-type="supplementary-material"}), were produced by the culture of marine deep sediment strain *Paenibacillus profundus* Sl 79. The compound **(245)** was cytotoxic to SK-MEL-28 cell line (IC~50~ = 3.07 μM after 72 h) and also inhibited the growth of *S. aureus* (ZOI 24 mm), *S. epidermis* (ZOI 20 mm), *B. subtilis* (ZOI 28 mm) and *Enterococcus faecium* (ZOI 11 mm) (Kalinovskaya et al., [@B61]).

Role of genomics, proteomics and bioinformatics in discovery and development of nonribosomal peptides drugs {#s6}
===========================================================================================================

The non-ribosomal peptides (NRPs) are an essential source of chemical diversity for drug discovery and development. At present, there are more than 1,164 different non-ribosomal peptides known in public database (NCBI) which consists of over 500 unique monomers, including both proteinogenic and non-proteinogenic L- and D-amino acids as well as carboxylic acids and amines (Caboche et al., [@B15]). Due to great structural diversity (linear, cyclic and branched or other complex primary structures) these complex secondary metabolites had impact on all therapeutic area, as making them suitable to be used as clinical agents. However, such potential NRPs often need to be modified to improve their clinical properties and/or bypass resistance mechanisms (Bush, [@B13]). For instance, FDA approved Oritavancin has been developed by using semi-synthesis strategy from Vancomycin for treatment of drug resistant skin infections (Markham, [@B89]). Indeed, modification in the nucleotide sequence of a natural NRPS gene or combining modules of different NRPSs may potentially lead them to be more effective with unique pharmacological activity. However, this requires in-depth understanding of both the assembly line and the resulting products. Over the last few decades several bioengineering approaches have been developed to increase the yields of NRPs and generating modified peptides with altered bioactivity or improved physicochemical properties (Winn et al., [@B177]). Earlier, biosynthetic generation of novel NRPs analogs focused on precursor directed biosynthesis (PDB) or mutasynthesis. In PDB, a wild-type organism is provided with modified or synthetic amino acids with the prospect that the substrate specificity of the relevant NRPS shall be flexible enough to allow addition of the modified precursors into the final peptide. However, mutasynthesis is the exact opposite. The modified substrates are fed to an engineered organism which lacks the enzyme(s) required for the biosynthesis of a specific natural precursor, so that a modified substrate or precursor analog may be effectively incorporated (Weist et al., [@B169]). These methods are important because they generate natural product analogs rapidly.

In earlier reviews many examples of precursor directed biosynthesis of NRPs are available (Thiericke and Rohr, [@B160]). Other methods being adopted for the production of new nonribosomal peptides is engineering of precursor supply *in vivo* or introducing tailoring enzymes from other pathways with new glycosylation, halogenation and sulfation enzymes being applied outside of their native clusters to create structural diversity. Although it\'s similar to precursor directed biosynthesis, it focuses mainly on endogenous biosynthesis rather than exogenous feeding. The introduction of halogen unit into NRP scaffolds has been a common target. For example, when the enzyme PrnA (a favin-dependent tryptophan-7-halogenase) from *Pseudomonas fuorescens* Pf-5 was expressed alongside the NRPS genes for the uridyl peptide antibiotic pacidamycin, produced by *Streptomyces coeruleorubidus*, a new halogenated analog was generated (Roy et al., [@B137]). Using such a technique enduracidin analogs have been produced by altering halogenase in wild-type *Streptomyces fungicidicus* (Yin et al., [@B182]). An alternative but complicated strategy has also been developed to generate novel NRPs. It exchanges NRPS subunit, module, and domain of the core peptide itself. Initially, this method was applied by Cubist Pharmaceuticals for the development and marketing of nonribosomal peptide antibiotic daptomycin, first natural product antibiotic that gained approval for clinical use in over 30 years (Baltz et al., [@B6]). Unfortunately, Cubist Pharmaceuticals failed to identify any daptomycin variants with better antibacterial property than parent daptomycin. Another route that has also been explored which involves modifying the length of the peptide chain by deletion or insertion of one or more modules (Mootz et al., [@B108]; Butz et al., [@B14]). A recent study indicates that the introduction of individual or combined point mutations in the binding pocket of an NRPS adenylation domain generates new diversity of NRPs (Han et al., [@B46]).

A latest technique called heterologous expression offer considerable promise especially for natural hosts which are slow growing, genetically difficult to handle, unculturable, or even unknown. The transfer of biosynthetic genes from the original microbial organisms to more amenable heterologous host bacteria is more amenable to large-scale fermentation production would overcome the limitation of procurement of the drug from the ocean (which is currently limited to expensive aquaculture or field harvesting) and ensure supply (Ongley et al., [@B122]). The gene cluster responsible for polyketide epothilone (a potential anticancer agent) biosynthesis in the myxobacterium *Sorangium cellulosum* was cloned and completely sequenced by Tang et al. ([@B154]). Concomitant expression of these genes in the actinomycete *Streptomyces coelicolor* produced epothilones A and B (Tang et al., [@B154]). After this heterologous expression system portends a plentiful supply of this medically relevant agent. Similarly A novel gene (amyZ) encoding a cold-active and salt-tolerant α-amylase (AmyZ) was cloned from marine bacterium *Zunongwangia profunda* (MCCC 1A01486) and the protein was expressed in *Escherichia coli* (Qin et al., [@B134]). The Ptchi19 gene of the marine *Pseudoalteromonas tunicata* CCUG 44952T was cloned and expressed in *E.coli* (García-Fraga et al., [@B37]). A new κ-carrageenase gene from marine bacterium Zobellia sp. ZM-2 was cloned and expressed in *E.coli* (Liu et al., [@B76]). Heterologous expression of the barbamide biosynthetic gene cluster from the marine cyanobacterium *Moorea producens* in the terrestrial also led to the production of a new barbamide congener 4-O-demethylbarbamide (Kim et al., [@B63]). The biosynthetic pathway for bacitracin was successfully transferred from *Bacillus licheniformis* to the related species *B. subtilis* (Eppelmann et al., [@B30]). The polyketide biosynthesis pathway for the marine-derived telomerase inhibitor griseorhodin A was productively transferred to *Streptomyces lividans* from an environmental *Streptomyces* isolate (Li and Piel, [@B72]). Ugai et al. ([@B165]) got success in heterologous expression of the cryptic gene cluster found in *A. solani* to obtain a marine-derived antifungal agent didymellamide B from the *A. oryzae* transformant introducing PKS--NRPS, *trans*-ER, and P450 genes *asolSCA* (Ugai et al., [@B165]). Likewise many other successful examples are available in literature (Fortman and Sherman, [@B35]; Luo et al., [@B82]; Winn et al., [@B177]).

All studies presented above for production of novel NRPs and engineering NRPS assembly lines in the native host are laborious having low throughput and low yield. Recent advances in genome sequencing, gene synthesis, metabolomics and bioinformatics revolutionized the process of NRPS engineering. In-silico based bioprospecting of available microbial genome sequences gives us a quick look at the hidden biosynthetic capacity of natural products in the microbial species. Several active as well as silent enzymes have been identified in fungal and bacterial genomes which are involved in the biosynthesis of NRPs. The corresponding secondary metabolites of these enzymes have not been identified to date (Brakhage, [@B11]; Doroghazi and Metcalf, [@B26]). Various powerful computational algorithms and tools have been developed to analyze BGC and to determine whether they are likely to encode unique compounds (Medema and Fischbach, [@B96]). Comprehensive ranges of software tools are available for identification of BGC in genome sequences. These tools are generally divided into two categories: high-confidence/low-novelty and low-confidence/high-novelty. High-confidence/low-novelty includes tools such as CLUSEAN13, ClustScan14, np.searcher15, SMURF16 and antiSMASH (Medema et al., [@B97]). These tools analyze Hidden Markov Models (HMMs) with manually curated cutoffs to identify signature genes or domains that are highly specific for known classes of biosynthetic pathways. Such strategies give a quick and reliable interpretation of NRPs gene cluster of a single strain from its genome sequence. Low-confidence/high-novelty mainly focuses on the identification of new BGC types by applying three approaches; namely pattern-based mining, phylogenetic mining and comparative genomic mining. These further include Cluster Finder, EvoMining, and Algorithim, respectively. Tools for identification of BGCs with respect to metagenomes include PCR-based sequence-tag and the shotgun assembly approach. The sequence-tag approach identifies clones from selected harbor pathways in metagenomic libraries by amplifying known biosynthetic domains using PCR. This is particularly useful for identifying variants of known pathway types. This has been also used to identify gene clusters encoding close relatives of molecule such as rapamycin, teicoplanin, and thiocoraline (Owen et al., [@B124]). However, the tag-based approach can be used to find entirely new molecules that are produced by known BGC classes, especially when coupled with phylogenomic tools such as NaPDoS (Ziemert et al., [@B189]). These tools find application in identifying domains that represent new areas of the extant biosynthetic diversity. A range of systems have been developed to predict the substrate specificities of NRPS adenylation domains (Röttig et al., [@B136]; Prieto et al., [@B131]). Tools such as NP.searcher and antiSMASH individual monomer predictions are then combined to give a rough idea of the core scaffold of a nonribosomal peptide. Simultaneously, advancement in mass spectrometry gives efficient dereplication for analysis of small-molecule products of biosynthetic pathways (Nielsen and Larsen, [@B115]). NRPQuest algorithm uses molecular networking approach to identify potential gene clusters for observed tandem mass spectra of NRPs (Mohimani et al., [@B105]). The search database for NRPquest generates all possible orders of NRPS assembly lines within each detected NRP BGC hence, predicting the amino acids encoded by each of its module using NRPSPredictor2 (Röttig et al., [@B136]). A chemoinformatic based library and informatic search strategy for natural products (iSNAP) has also been doveloped for true nontargeted dereplication across a spectrum of nonribosomal peptides and within natural product extracts (Ibrahim et al., [@B55]). It is clear that the tools and techniques discussed above have accelerated the discovery and development of novel NRPs with desirable biological activities.

Conclusion and future prospects of marine derived nonribosomal peptides {#s7}
=======================================================================

Marine chemicals often possess quite novel structures which in turn lead to pronounced biological activity and novel pharmacology. The study of such chemicals, therefore, is a very promising endeavor. There are three parallel branches in marine natural products chemistry: marine biomedicinals, marine chemical ecology and marine toxins. Integration of these three fields of study gives marine natural products chemistry its exclusive character and vigor. The search among marine chemicals for medically useful agents involves two steps, discovering the type of biological activity and studying the pharmacological mechanism of the activity. It is now clear that efforts to date in marine natural product chemistry have largely focused on easily collected microorganisms and their major metabolites, and while there has been a recent shift to, as detailed above, minor metabolites present in very small quantities are a challenge for analytical and biological evaluations.

As has been demonstrated in this review, the potential for nonribosomal peptides from marine as sources and/or leads to drugs that have pharmacological effects (i.e., cancer and anti-infective) is only now being realized. Combining enzyme technology and solid phase peptide synthesis, it is possible to generate a vast variety of unique peptides composed of non-proteinogenic amino acids with unique pharmacological and biotherapeutic potential. It is possible that in coming years at least one or more marine derived novel nonribosomal peptide will enter into commerce as a drug. In concluding, the huge ranges of nonribosomal peptides that have so far been identified from marine resources frequently have no comparable equivalent in terrestrial organisms. The work by (predominately) young investigators on the many aspects of nonribosomal peptides (like biosynthesis) in the commensal and/or symbiotic microbes associated with these invertebrates, or in the microbes isolated from shallow and deep sediments will increase the numbers of nonribosomal peptides from marine for further work. The marine system has hardly been scratched as yet!
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